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Abstract
Background and aims: Diffuse malignant mesothelioma of the pleura, also called malignant pleural 
mesothelioma (MPM), is a rare cancer arising from mesothelial cells. The current clinical tumor, node, 
metastasis (TNM) staging is based on computed tomography (CT) findings, which lack accuracy,
especially in the evaluation of MPM tumor extent. To date, there are no circulating biomarkers available 
that can be used for diagnosis or to evaluate prognosis. Despite recent advances in the management of 
MPM overall survival remains poor, ranging from 9 to 12 months. Current treatment options include
chemotherapy, radiotherapy, and surgery either alone or in combination. Patient’s performance status, 
age, sex, and histological subtype are currently the strongest clinical prognostic factors that also guide 
management. The primary aims of this study were to search for radiological, histopathological, and 
clinical prognostic factors in MPM focusing on the specific tools available in our research environment.
In addition, we aimed to define a novel and practical way to estimate tumor size (TS) from a CT and to
assess the prevalence of cancer cachexia in MPM patients. Finally, we also aimed to evaluate the role of 
circulating activins and follistatins and to confirm previously observed preclinical associations in MPM
patients.
Material and methods: Using the Finnish Cancer Registry all MPM patients diagnosed in Finland 
between 2002 to 2012 were identified. They formed the population group used for studies I, III, and IV.
Data was collected from various national registries including hospital medical records. In the first study, 
we reviewed the CT characteristics of 161 patients at the Helsinki University Hospital region. Tumor
size was estimated by using the maximal tumor thickness and grading tumor extension along the chest 
wall. In studies III and IV, we identified a subcohort of patients (n = 52) from the cancer registry with 
survival over five years, characterized as a long-term survivals (LTS). The epithelioid subgroup from 
study I formed the control group (n = 84) in these studies. We conducted a thorough clinical and 
histopathological evaluation in these patients, in order to confirm the initial diagnosis and to search for 
prognostic features. In study II, we prospectively enrolled 106 patients with suspected thoracic 
malignancy from June 2016 to January 2018. Pretreatment blood samples were obtained and activins 
and follistatins levels were quantified using enzyme-linked immunosorbent assay. Since activins are 
associated with cancer cachexia, we investigated the prevalence of cachexia in MPM. Patients were 
defined as cachectic if they had prior weight loss with or without CT-based sarcopenia. A subset of 
MPM patients was evaluated for chemotherapy response. The Cox’s proportional hazard model was 
used to estimate the strength of the association between various factors and survival. Multivariate logistic 
or linear regression analysis was used to determine the independent influence of circulating biomarkers 
on cachexia or chemotherapy response. Analyses were performed using the SAS System for Windows 
(SAS institute, Inc. Cary, NC, version 9.4) or SPSS (IBM SPSS Statistics, Chicago, version 24.0 or 
25.0). 
Results: We found that TS estimation was reproducible and was associated with sarcomatoid histology 
and TNM stage. In multivariate analyses, high TS (p < 0.001) as well the amount of pleural effusion (p 
< 0.001) were the only CT characteristics associated with survival. Similarly, patients with epithelioid
histology had the best prognosis (p < 0.001). Within the epithelioid subgroup, we found that TS (p = 
0.004), performance status (p < 0.001) and treatment were associated with survival (p = 0.005). Low 
nuclear grade (p < 0.001) and the presence of exophytic polypoid growth (p = 0.008) were the only 
independent histopathological features related to prolonged survival. Twelve (57%) MPM patients were 
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assessed as cachectic at diagnosis. Among the studied biomarkers, activin A was the best one at 
separating the main study groups: it was elevated in MPM compared to non-small cell lung cancer or 
benign lung tumor patients (p < 0.001). Activin A associated also with cancer cachexia (p = 0.001),
pretreatment TS (r = 0.549; p = 0.010) and chemotherapy response (p = 0.0028).
Conclusions: We found that TS, performance status, and histological subgroups were the strongest 
predictors of mortality. In the epithelioid subgroup, nuclear grade and polypoid growth pattern were the 
most robust prognostic factors. Finally, we found that activin A could be a useful biomarker in MPM 
for the association with cancer cachexia, TS, and chemotherapy response.
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1. Introduction
Malignant mesothelioma (MM) is a cancer arising from mesothelial cells. Pleura is the most common 
location, followed by the peritoneum, and in rare cases the pericardium and tunica vaginalis. The 
incidence of MM in Finland is slowly declining, with approximately 80 to 100 annual new MM diagnosis
[1]. Previous asbestos exposure is the most common risk factor of MM, which is believed to cause nearly 
80% of cases worldwide.
Malignant pleural mesothelioma (MPM) patients typically present with dyspnea, which is frequently 
associated with chest pain, cough, signs of systematic disease such as weight loss, anorexia, malaise, 
and fatigue [2]. The most common clinical finding in MPM patients is ipsilateral pleural effusion, which 
is the main reason for dyspnea. The mesothelioma spreads mainly through local invasion, and distant 
metastasis occurs usually only in advanced stages of the disease.
Imaging plays an essential role in the diagnostic assessment, guidance of treatment decisions, and 
follow-up evaluation of MPM patients. The radiological appearance of MPM is non-specific and can 
range from pleural effusion to pleural thickening and to a lobulated mass. An irregular rind-like growth 
pattern makes the radiological assessment challenging. Contrast-enhanced computed tomography (CT) 
of the chest and upper abdomen is the main imaging modality. In some cases, magnetic resonance 
imaging (MRI) or positron emission tomography (PET) can provide useful information [3]. The 8th
edition of the American Joint Committee on Cancer/Union for International Cancer Control the tumor, 
node, and metastasis (TNM) staging system is currently recommended for staging the disease [4].
Previous studies have suggested that measurements of tumor thickness and/or tumor volume by CT 
could not only help assess treatment response but also have prognostic value, and therefore could 
supplement the current tumor burden evaluation [5,6].
Multiple circulating biomarkers have been studied regarding diagnosis, disease monitoring, prognosis, 
and screening. Previous studies have identified that serum levels of mesothelin or soluble mesothelin-
related peptides, megakaryocyte potentiating factor, osteopontin, and fibulin-3 are elevated in MPM 
compared to asbestos-exposed or secondary pleural malignancies [7]. However, multiple confounding 
factors exist, and none of these markers are accurate enough for clinical use. Thus to date, circulating 
biomarkers do not contribute to the current diagnostic or treatment guidelines [8,9]. Activins belong to 
the transforming growth factor-ß superfamily and control cell proliferation and differentiation, among 
other biological functions. Activin signaling has multiple roles in carcinogenesis, and previous 
preclinical studies have found that both activin A and B are overexpressed in MPM tumor tissue and cell 
lines [10,11]. Similarly, a clinical study found that circulating activin A was elevated in MPM compared
to healthy controls and is associated with poor prognosis in the epithelioid subtype [12]. Furthermore, 
previous animal and clinical studies have shown that the activin pathway is associated with cancer 
cachexia, cancer-related bone loss, and resistance to platinum-based chemotherapy [13–15]. These 
findings suggest that activins may be interesting biomarkers that could aid diagnosis and have possible
prognostic or therapeutic value.
Diagnosis can be difficult due to the rarity and heterogeneity of the tumors. The cornerstone of the 
diagnosis is the histopathological confirmation of invasive tumor growth, together with clinical and 
radiological findings pointing towards a diagnosis of MPM. The most reliable tumor tissue sample can 
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be achieved via thoracic surgery, mostly video-assisted thoracoscopic surgery (VATS). Other diagnostic 
options include transthoracic needle biopsy or medical thoracoscopy. Differential diagnosis consists of 
other primary pleural tumors, pleural metastasis of other origins, benign reactive mesothelial 
proliferation, and other mesotheliomas [16]. Immunohistochemical staining is the most important 
supplementary technique that discriminates MPM from other benign or malignant pleural diseases [17].
MPM is usually diagnosed in its advanced stage, when treatment options are scarce. Even in the early
stages of the disease, it is not possible to achieve a microscopically complete (R0) surgical resection due 
to unique growth patterns in the pleural cavity [18]. Thus, the current treatment options include
chemotherapy, radiotherapy, and surgery either alone or in combination [8]. Despite the progress in 
treatments in recent years, the prognosis of MPM patients remains dismal. The overall survival in 
population based studies varies from 9 to 12 months, and a 5-year survival rate is approximately 5%
[19,20]. The longest survival times have been reported on patients undergoing multimodality treatments, 
with median survivals ranging typically from 19 to 25 months [21]. Long-term survival (LTS) is rare, 
and has been studied mainly in patients treated with surgery or multimodality treatment regimen [22].
The proposed prognostic factors include clinical variables, radiological parameters at presentation, and 
pathological or molecular findings in the tumor tissue. The most consistent clinical characteristics of 
prolonged survival patients are young age, absence of weight loss, female sex, and good performance 
status [20,23]. A small radiological tumor burden assessed either by TNM stage, tumor thickness, or 
volumetry is also associated with a better prognosis [6,24]. Histological subtyping of MPM is one of the 
most important prognostic factors and the epithelioid subtype is the most common form with the best 
prognosis [25]. Within the epithelioid subtype, several different prognostic features have been proposed 
in the literature, such as a nuclear grading scale and morphological subtypes [17].
The primary purpose of this study was to confirm previously observed findings as well as to look for 
novel, patient-related, radiological, and histopathological prognostic factors in MPM. To do so, we 
identified and verified a subset of MPM patients from the Finnish Cancer Registry. Data was collected
and combined using the social security number from various governmental registers including individual 
hospital medical records. Secondly, we studied a set of novel biomarkers, namely activins and 
follistatins, in a prospective cohort that was collected with the newly established Helsinki Biobank. We 
aimed to confirm previous findings, in their association with MPM, and clinically important endpoints
such as stage, tumor size, cancer cachexia, and chemotherapy response.
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2. Review of the literature
 
2.1 Pleural anatomy and physiology
2.1.1 Pleural anatomy
The pleural mesothelium is a monolayer of mesothelial cells derived from the embryonic mesoderm. 
Mesothelial cells rest on a submesothelial layer of connective tissue with a basal lamina following a 
well-defined elastic layer. Under it there is loose connective tissue layer containing adipose tissue,
mononuclear cells and blood vessels, nerves and lymphatic lacunas. The deepest layer, a fibroelastic
layer, merges the pleura with underlying structures [26]. The pleura is divided into the visceral and 
parietal pleura, which are united in the hilum to form the pleural cavity [27]. The parietal pleura covers 
the chest wall, diaphragm and mediastinum, whereas the visceral pleura lines the outer surface of the 
lung including interlobar fissures [28]. The normal combined thickness of the pleura is 0.2 to 0.4 
millimeters, while the pleural space width is 10 to 20 micrometers [29].
2.1.2 Physiology of the pleura
A thin layer of liquid is present between the pleural surfaces and acts as a lubricant during respiratory 
movements. It is estimated that approximately 0.25 ml of pleural fluid per kilogram of body weight is
produced daily. The parietal pleura is responsible for the majority of pleural fluid turnover. The amount 
of pleural cavity fluid is dependent on the balance of hydrostatic and oncotic pressure differences 
between the systemic and pulmonary circulations and pleural space [30]. The fluid is produced through 
the parietal pleura by net filtering pressure gradient and reabsorbed by lymphatic vessels [31]. Most 
pleural diseases manifest by progressive pleural effusion either by incremental production or decreased 
reabsorption.
Traditionally, the mesothelial layer was seen as a protective layer with no physiological function. 
However, it is now recognized to be responsible for the majority of pleural functions including fluid and 
cell transportation, inflammatory response, tissue repair, and antigen presentation [32]. Mesothelial cells 
are metabolically active cells that produce cytokines and growth factors such as TGF-ß, nitric oxide, 
glycosaminoglycans, and surfactant [33].
2.2 Malignant pleural mesothelioma (MPM)
2.2.1 Definition
Malignant mesothelioma (MM) is a type of cancer arising from mesothelial cells which line the pleural 
cavity and also the peritoneum, pericardium and tunica vaginalis. From these sites, pleural mesothelioma 
is the most common, including approximately 75%-80% of diagnosed MM cases, in contrast to 
peritoneal which include 10% to 20% and single reported cases of pericardial and tunica vaginalis [34].
The epidemiology, pathogenesis, prognosis, and clinical behavior differs depending on the origin of the 
disease.
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The term malignant pleural mesothelioma (MPM) refers to a diffuse malignant mesothelioma of the 
pleura. It is the most common type of mesothelioma and needs to be distinguished from other 
mesotheliomas (Table 3).
2.2.2 Clinical presentation
At the early stage of MPM, either single or multiple small nodules or plaques arise from the parietal 
pleura. The pleural surface becomes progressively thicker as the tumor invades the pleural cavity [35].
In the later stages of the disease, growing tumor encases surrounding organs. The tumor typically spreads
through local invasion from the parietal to the visceral pleura and into the chest wall, mediastinum, 
diaphragm, pericardium or spinal cord [36]. Subcutaneous invasion through a percutaneous procedure 
tract (i.e. after biopsy, chest tube, thoracoscopy) is reported in approximately 20 % of MPM patients 
[37]. Distant metastasis is thought to happen only in advanced stages either via lymphatic or 
hematogenous tumor spread. A clinical study on 165 MPM patients found parenchymal lung metastasis 
in 27%, bone metastasis in 20%, peritoneal carcinosis in 24%, and additional visceral organ involvement 
in 15% of patients [38]. Autopsy studies have reported distant metastases in lung, liver, adrenal glands,
bone, brain, spleen, or kidney in up to 55% of deceased MPM patients [39].
The tumor usually presents unilaterally, although three percent of patients have bilateral malignant
disease at presentation [40]. The average time between the onset of symptoms and MPM diagnosis is 
two to three months [2]. The symptoms are non-specific and depend on the stage of the disease. Only a 
small number of patients are asymptomatic at diagnosis. Shortness of breath (dyspnea) and chest pain
are the most frequent symptoms [2]. Dyspnea can be either due to pleural effusion or due to diminished 
respiratory movements and encasement of the lung by the tumor itself. A retrospective study focusing 
on clinical and radiological findings in 363 MPM patients showed that pleural effusion was present in 
86% of diagnosed patients out of which 82% had reported breathlessness [41]. Chest pain was the second
most common symptom at diagnosis, occurring in 68% of patients. Pain can be due to dull parietal 
pleural irritation or due to tumor invasion into the chest wall causing somatic or neuropathic pain [36].
Cough and hemoptysis are uncommon but possible signs of the disease. Systemic symptoms such as
fatigue, malaise, anorexia, night sweats, and weight loss are typically present in the late phase of the 
disease. 
A rare presentation of MPM can be direct tumor infiltration into the mediastinum causing dysphagia, 
phrenic nerve paralysis, or superior vena cava syndrome [42]. Similarly, tumor compression of the spinal 
cord may lead to focal neurologic deficits, and growth through the diaphragm could result in abdominal 
pain, nausea, and vomiting. Cardiac involvement may lead to pericardial effusion, heart failure, or 
arrhythmias [36].
2.2.3 Epidemiology
MPM is a rare cancer estimated to represent less than one percent of all diagnosed malignancies [43].
The incidence of MPM follows mostly the regional use of asbestos, and has been increasing steadily in
the last decades worldwide [44]. Data from Cancer Registry of Norway includes incidence rates between 
1970 and 2009. They found that the incidence has increased 7.8-fold in men and 6.5-fold in women in 
this 40-year period. The age-adjusted annual increase was 4.2% in men and 2.9% in women [45]. A
similar rise in incidence has been reported in the UK and in some other European countries with peak 
incidences being expected in ten years [20,44]. In contrast, in the USA the age-adjusted incidence rates
of MM peaked in the early 1990s, followed by a decrease [46]. Likewise, the reports from the Finnish 
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Cancer Registry (FCR) show that the age-standardized incidence of MM increased with small annual 
variation from 1953 (0.06 / 100,00) to peak year 2007 (2.23 / 100,000) and started to decrease after that 
(1.48 / 100,000 in the year 2017) [1]. Figure 1 shows the variability of incidence both in men and women 
in Finland from 1953 to 2017. 
 
The largest European epidemiological MPM cohort reported in the literature comes from the UK, where 
they analyzed 8740 cases from the UK National Lung Cancer Audit between 2008 to 2012 [20]. The 
median age at diagnosis was 73 years with a range between 21 to 100 years of age. Eighty-three percent 
of the patients were male. Similar results were published in Finland including a total of 1010 MPM 
patients between the years 2000 – 2012 and identified from FCR: median age was 69 years (range 25 – 
96 years) and 79% were male [19].  
 
 
 
 
 
Figure 1. Malignant mesothelioma incidence in Finland from 1953 to 2017. Reproduced with permission from 
the Finnish Cancer Registry [1] 
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2.2.4 Risk factors
Asbestos exposure
Asbestos is the commercial term for naturally occurring fibrous minerals that are found in many parts of 
the world. Its fibrous shape, strength, and resistance are the main reasons for the global use of asbestos 
fibers [47,48]. Asbestos fibers are classified into two main families based on their geological origin. The 
amphiboles include crocidolite, amosite, tremolite, actinolite, and anthophyllite. The serpentines contain 
only chrysotile, which is the only asbestos type that is still widely used [49].
Asbestos exposure is the biggest risk factor for MM, and it is estimated to account for 70% to 90% of 
new MPM diagnoses [50]. Even a brief exposure to asbestos can result in MM. The association between 
asbestos exposure and MM was first described in 1960s, when Wagner et al. found a high incidence of 
MM in asbestos workers and among people living near a crocidolite asbestos mining area [51]. A review 
of 1690 mesothelioma cases found that the median latency period from exposure to disease was 32 years 
and over 99% of patients had a latency of over 15 years [52]. Asbestos exposure increases also the risk 
of lung cancer and other malignancies including laryngeal and ovarian cancer. Asbestos has also been 
identified as a risk factor for benign pleural diseases such as pleural plaques or exudative pleuritis,
fibrosis of the lung (asbestosis) and retroperitoneum [47,53,54].
Historically, the majority of asbestos exposure has been occupational. Epidemiological analyses from 
France showed that the industries with the highest risks of MM among asbestos industry were
shipbuilding and repairing, construction, and manufacture of metal construction materials, while the 
occupations at highest risk were plumbers and pipe-fitters, welders, and sheet-metal workers [55].
Finland banned the use of new asbestos in 1992. The European Union adopted a Directive which banned 
all remaining uses of asbestos in 2005 [56]. In addition, a national law in Finland was introduced in 2016 
to reduce the risk for exposure in demolition and renovation work of old buildings. However, despite 
the knowledge of hazardous effects of asbestos, there is still a marked industrial use of asbestos in some 
parts of the world [49]. Asbestos exposure can be also non-occupational. A meta-analysis reviewed the 
risk of MPM in non-occupational asbestos exposure using 18 studies comprising 665 MPM patients. 
They found that non-occupational asbestos exposure increases the risk for MPM by 5.4-fold in
household (i.e. home installation/renovation, para-occupational) and 6.9-fold in neighborhood (i.e. air 
pollution, industrial contamination) exposure [57].
Other risk factors
Similar to asbestos, other organic or mineral fibers can be carcinogenic and have an association with 
MPM [35]. For example, erionite, which is found in volcanic regions in Turkey, Italy, and USA has been 
linked to a high incidence of MPM [58]. In addition, carbon nanotubes have physical similarities with
asbestos and are used widely in the electronic industry. They have shown in vitro cytotoxicity and 
development of MM in animal models [59]. A variety of tumors, including MPM, have been reported 
after either therapeutic or occupational exposure to ionization radiation [60]. There is contradictory 
evidence about the role of simian virus 40 in MPM; some animal and epidemiological studies have found 
a strong relationship for the risk of MPM but others have questioned these results and the International 
Agency for Research on Cancer (IARC) has classified it as not carcinogenic [61,62]. On the contrary to 
other thoracic cancers, no clear association between tobacco smoke and the risk of MPM has been 
established.
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2.2.5 Pathogenesis
Asbestos induced carcinogenesis
In the 1980s, Kane et al observed that a single dose of asbestos fibers can damage the mesothelium,
stimulating the recruitment of inflammatory cells to the site of the injury, which subsequently leads to 
mesothelioma development [63]. Inhaled asbestos fibers enter the parietal pleura through the alveoli or 
the lymphatic vessels of the pleural space [64]. A dose-response relationship between asbestos exposure 
and the risk for MPM has been proposed in epidemiological, animal, and lung tissue fiber burden studies 
[65,66]. However, the exact mechanism of asbestos carcinogenicity is still unknown. The hallmark of 
carcinogenicity of asbestos fibers is their long biopersistence and their ability to induce pleural irritation 
and local inflammation [67].
Currently, there are several hypotheses trying to explain the molecular mechanism of asbestos-induced 
pathogenesis. Firstly, the asbestos fibers themselves or the macrophages trying to digest them induce 
oxygen free-radicals that lead to intra-cellular deoxyribonucleic acid (DNA) damage and abnormal 
repair [68,69]. Secondly, asbestos fibers can tangle with chromosomes and the mitotic spindle, leading 
to chromosomal changes in dividing mesothelial cells [70]. Thirdly, asbestos fibers contain a variety of 
proteins and chemicals that cause cellular damage [68]. Fourthly, asbestos-exposed mesothelial cells and 
macrophages release several cytokines and growth factors that induce inflammation and increase cellular 
damage [71]. These markers induce activation of the nuclear factor-κB signaling pathway, which 
promotes mesothelial cell survival and division rather than apoptosis after asbestos exposure. Finally, 
dysregulated mesothelioma cells gain a growth advantage through stimulating factors such as epidermal 
growth factors, transforming growth factor-β (TGF-β), platelet-derived growth factor A, and angiogenic 
vascular endothelial growth factor (VEGF) [67]. Moreover, 90% of MMs express telomerase, which 
prevents telomere shortening, leading to continuous cell divisions [72].
Genetics of MPM
Normal cell growth is controlled by genetic material containing chains of DNA. Alterations in the DNA,
referred to as mutations, can be either inherited (i.e. germline) or spontaneous (i.e. somatic). Somatic 
mutations include true spontaneous, as well as induced mutations such as those caused by asbestos. 
Instead of somatic mutations, germline mutations are passed from parents to offspring. In addition to 
germline mutations, additive somatic mutations are needed to develop an uncontrolled, cancerous, cell 
growth [73]. It is estimated that 5% to 10% of all cancers result from germline mutations, and certain 
gene defects can develop a variety of cancers known as familiar cancer syndromes [74].
The genetic landscape of MPM consists both inter- and intra-tumoral heterogeneity. The actual number 
of genetic mutations in cancer cells is usually low compared to other solid cancers [75,76]. Either 
sporadic or germline mutations of tumor suppressive genes contribute to the most common genetic 
changes in MPM. Tumor suppressor genes prevent cells from growing and dividing uncontrollably. The 
most frequently mutated gene found in MPM is BAP1, which encodes a nuclear deubiquitinase that 
regulates transcription factors and repairs double-strand DNA breaks [76,77]. Inactivation of the BAP1
promote both genomic instability and reduced cell death, which favors malignant growth. BAP1
mutations can be found in approximately 60% of mesotheliomas, which includes both sporadic and 
familial cases [75]. Other frequent inactivating mutations found in two recent and comprehensive 
analysis consisting almost 300 MPM cases were NF2, CKDN2A, TP53, LATS2, SETD2, DDX3X, ULK2,
RYR2, CFAP45, SETDB1, and DDX51 [76,78]. In addition, many other gene alterations have been less 
frequently reported [79]. Based on these findings, it is likely that several mutations are needed to 
accumulate for MPM development. These genetic mutations lead to several alterations in intracellular
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signaling pathways which regulate cell growth, proliferation, and survival including the p53 signaling,
Hippo cell cycle, DNA repair, MAPK, ribonucleic acid (RNA) helicase, histone methylation, and 
PI3K/AKT/mTOR pathways [78,79].
The observation that only 5% to 15% of asbestos exposed people will develop MPM, suggests that 
inherited factors may affect the susceptibility to asbestos exposure. The observation that MM clustered
in certain families with small environmental asbestos/erionite exposure led to the finding of germline 
mutations in the gene encoding BAP1 in multiple relatives with MM [80]. Subsequently, rodents that 
carry one abnormal copy of BAP1 were exposed to low levels of asbestos and developed frequent and 
accelerated MM [81]. The defect in germline BAP1 gene has been confirmed to also cause other cancers 
such as skin or uveal melanomas, renal cell carcinomas, breast carcinomas, sarcomas, and brain tumors 
[82]. After the initial finding of BAP1, several other germline cancer susceptibility mutations have been 
found; one study found 24 mutations in 13 genes in 198 patients (12 % of tested patients) [83]. BAP1
was the most common mutation including 3% of tested patients, while other germline mutations were in 
genes BRCA1-2, CHEK2, CKDN2A, ATM, MRE11A, TP53, MSH6, TMEM127, SDHA, VHL, WT1. The 
clinical characteristics associated with germline mutations were peritoneal MM comparing with pleural 
disease, minimal-to-no asbestos exposure, young age, second cancer, or another MPM in the family.
2.2.6 Imaging
Imaging plays an essential role in the diagnosis, guidance of treatment decisions, and follow-up 
evaluation of MPM patients. Computed tomography (CT) is the primary radiological method used in the 
assessment of MPM, whereas magnetic resonance imaging (MRI) or positron emission tomography 
(PET) can also prove useful information in some cases [3]. However, MPM cannot be distinguished 
from other pleural malignancies solely from imaging, and the majority of the published literature 
concentrates on the differences between benign and malignant pleural disease in general.
Imaging modalities in MPM diagnosis
Chest X-ray is usually the first radiological examination used when pleural disease is suspected. 
However, its clinical benefits are narrow as it can only reveal suspicion of pleural tumor, effusion or 
plaques [84]. Ultrasound (US) is a high frequency sound wave. Pleural US is usually used to confirm 
the suspicion of pleural disease detected in X-ray. Pleural effusion aspiration or needle-biopsies of 
abnormal pleura are done using US-guidance [85]. Moreover, contrast-enhanced US showed sensitivity 
of 98% and specificity of 95% in differentiating malignant and benign pleuropulmonary lesions although 
this method has not been largely studied [86].
CT is an X-ray imaging method, which digitally produces three-dimensional images [87]. CT of the 
chest and upper abdomen is the most used technology in MPM evaluation, as it demonstrates the extent 
of primary tumor, its local invasion, intrathoracic lymph nodes, and extrathoracic metastasis.
Intravenous contrast should be administered in order to achieve tissue enhancement, which aids in the 
differentiation of malignant and benign lesions. The diagnostic accuracy of CT in 370 suspected pleural 
malignancy patients resulted in sensitivity of 68%, specificity of 78%, positive predictive value of 80%, 
and negative predictive value of 65% [88]. These numbers suggest that a significant proportion of 
patients with pleural malignancy have no evident malignant findings in the CT scan. Pleural mass, and 
a focal or diffuse pleural thickening of more than 1 cm is suggestive of malignant pleural disease. Seely 
et al evaluated diagnostic CT scans of 92 histologically confirmed MPM patients; all patients had some 
form of pleural mass or thickening: costal in 97%, mediastinal in 95%, paravertebral in 92%, 
diaphragmatic in 76%, fissural in 72%, whereas the thickening was nodular in 79 patients (86%). Pleural 
effusion was found in 87% and calcified pleural plaques in 43% [40]. In addition to pleural thickening,
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tumor volume evaluation either by manual or semi-automatic CT protocols have been proposed but 
additional data is needed for wide clinical use [89]. Modified Response Evaluation Criteria in Solid 
Tumors (mRECIST) criteria is mesothelioma specific and currently recommended for therapy response 
assessment. It combines unidimensional tumor thickness measurements at two sites in three different 
levels on axial CT scans into one measure. It was originally published in 2004 with a newly revised 
version published in 2018 [90,91].
MRI is based on the magnetization properties of hydrogen protons. The minor contrast differences 
between tissue lines can be effectively characterized using MRI, which makes it better to visualize soft 
tissue pathologies compared to CT [92]. Functional MRI, such as diffusion-weighted imaging, is a 
promising novel method for oncologic applications. It can be used non-invasively to quantify diffusion 
of water molecules in tissues. A prospective study investigated its differential ability on pleural 
malignancy and reported a sensitivity of 93%, specificity of 94%, and accuracy of 94% [93]. Another 
study showed that novel MRI applications can help to diagnose histologic subtypes of MPM, and to 
recognize intratumor distribution of sarcomatoid or epithelioid components [94]. However, to date, its
clinical applicability has not been well defined.
PET is a form of nuclear imaging, where a positron emission from the radioactive tracers is detected by
the PET scanner [95]. PET scan provides information on tissue metabolism, which differs from 
previously discussed modalities as they rely on anatomical changes. PET scan produces three-
dimensional images but has a poor anatomic resolution, thus it is usually combined with CT for the 
benefits of both techniques (PET-CT). Fluorine-18-deoxyglucose (FDG) reflects glucose metabolism, 
and is the most used radiotracer in clinical oncology [96]. Malignant cells show increased glucose 
utilization due to a high amount of glucose transporter proteins and enhanced glycolysis [97]. However, 
FDG uptake is not specific to malignancies: an increased metabolism detected by PET scan is also 
reported in several benign conditions, mainly due to inflammation or infection [98]. A meta-analysis
reviewed a diagnostic accuracy of PET-CT in differentiating benign and malignant pleural diseases [99].
They reviewed 16 studies with 745 patients and reported a pooled sensitivity of 95% and a specificity 
of 82%. Similarly, several studies have been published for diagnostic use of PET-CT in MPM. The 
sensitivity ranged between 88% to 92% and specificity between 75% and 93% depending on the 
underlying population [100,101]. A semi-quantitative analysis, called standardized uptake ratio (SUV), 
is frequently calculated using FDG ratios between cancer and non-cancer tissues [102]. Large differences
have been reported between the mean SUV of malignant (4.9 - 9.4) and benign (0.8 -3.3) lesions. One 
study revealed a sensitivity of 94%, specificity of 100%, positive predictive of 100% and negative 
predictive value of 93%, if the SUVmax was over 2.2 [100].
2.2.7 Staging
Staging refers to the sorting cancer patients into groups according to anatomical extent of the disease. 
Anatomical stage is used for treatment planning and prognostic evaluation. The American Joint 
Committee on Cancer (AJCC) and the Union for International Cancer Control (UICC) released a new, 
8th edition, staging manual for thoracic oncology in 2017 [4]. Historically, several different staging 
systems have been used in MPM. The first one was introduced by Butchart, including information of 
tumor extent in only 29 surgically treated patients [103]. Another frequently used staging method by
Brigham was proposed based on the tumor, resectability, and nodal status in patients undergoing
multimodality treatment [104]. In order to unify staging systems with other cancers, tumor-node-
metastasis (TNM) classification was introduced by the International Mesothelioma Interest Group
(IMIG) in the 1995 [105]. The IMIG staging was the first international MPM staging system that was
accepted by the AJCC/UICC. The problem in these previous staging systems is that they rely mostly in 
single-center surgical data. Thus, the International Association for the Study of Lung Cancer (IASLC) 
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and IMIG launched a large international staging database using retrospective information from 1995 to 
2009. However, this database lacked information on TNM-categories. Thus, for the newest 8th edition, 
a second IASLC clinicopathological database was created consisting of 2460 MPM patients [106]. Out 
of these patients, clinical staging information was available in 827, postsurgical in 830, and both in 803 
cases.
In the staging process, three main features are evaluated separately: the extent of local invasion of the
primary tumor (T), and presence or absence of lymph node metastasis (N) or distant metastasis (M). 
Two major changes were proposed in the new staging edition. Because there was no survival differences 
in the previous T1a and T1b categories, they were merged into single T1 [107]. In practice, this change 
means that no further distinctions are made if the tumor involves the parietal or visceral pleura. T3 and 
T4 tumors are both categorized as locally advanced with a difference that T3 tumors might still be 
potentially resectable, whereas T4-tumors are seen as technically unresectable (Figure 2). Similar to T-
category, the survival difference was found only in patients with negative nodes versus nodal metastasis,
but not between different nodal stations [107]. Thus, previous N1 and N2 stations were collapsed into 
new N1, which accounts for ipsilateral bronchopulmonary, hilar or mediastinal lymph nodes. Previous 
N3 will be reclassified as N2 including contralateral bronchopulmonary, hilar, or mediastinal and 
supraclavicular lymph nodes (Figure 3). There were no changes in M-category: patients are either 
categorized into presence or absence of distant metastasis. 
After assigning either clinical or pathological T, N, and M descriptors, they are categorized into different
stage groups (Table 1). Clinical stage refers to clinical and radiological information and is used to guide 
treatment options. Whereas pathological stage combines clinical stage with surgically obtained tissue 
samples and it gives a better assessment of prognosis and possible adjuvant therapy. It has been proposed
that only mesotheliomas diagnosed by maximal cytoreductive surgery should be pathologically staged, 
whereas less-invasive samples should undergo only clinical staging [108].
CT remains the primary method for clinical staging, although the correct clinical staging usually needs 
a combination of different diagnostic methods. In a comparison of MRI and CT for tumor extent 
evaluation, MRI was superior than CT in revealing chest wall, mediastinum or diaphragmatic muscle 
invasion and could lead to reclassification of up to 30% of surgical candidates [109,110]. In addition, 
MRI is the most accurate method for evaluating bone, cardiac, mediastinal, and central nervous system 
(i.e. brain or spinal cord) metastasis [111]. In nodal evaluation, a CT threshold greater than 10 mm in 
short-axis diameter is considered abnormal, but it is not specific for malignancy. The PET-CT has 
superior accuracy compared to CT for nodal metastasis assessment [111]. For occult distal metastasis, 
PET-CT discovers about 10% of metastasis that are not found on a CT. However, due to high false 
positive FDG uptake due to infectious or inflammation-related causes, invasive tissue sampling using
laparoscopy, endobronchial ultrasound or mediastinoscopy may be needed, especially if surgical 
treatment is considered [112]. In general, the correlation with clinical and pathological stage is poor, and 
upstaging has been reported in up to 80% of patients with cTNM stage I or II disease [113]. Thus, the 
latest guidelines suggest that staging is done mainly by contrast enhancement CT, but if radical surgery 
is considered, more intensive investigations should be done in order to define the precise clinical stage 
and inform appropriate treatment choices [8,9].
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Figure 2. Malignant pleural mesothelioma staging, T-stages [4] 
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Table 1: TNM stage with proportional prevalence according to “the best” overall stage (n = 2414); modified 
from AJCC/UICC Cancer Staging Manual 8th edition [4]
TNM, tumor, node, metastasis; AJCC, American joint committee on cancer; UICC, union for international 
cancer control. The best stage is defined as pathological stage if available, otherwise as clinical stage.
2.2.8 Circulating biomarkers
Circulating biomarker refers to measurable molecules from the bloodstream that reflect normal 
biological pathways, pathogenic processes, and/or response to an exposure or intervention. Ideally, a 
biomarker for cancer diagnosis should distinguish those with a specific type of cancer from those who 
do not have cancer. Further, it should also have high stability in the blood with simple, accurate, and
reproducible measurement method [114]. Many different circulating tumor markers have been studied 
in relation to diagnosis, disease monitoring, prognosis, or screening of mesothelioma [115]. Previous 
studies have demonstrated that blood levels of mesothelin or soluble mesothelin related peptides 
(SMRP), High Mobility Group Box 1, megakaryocyte potentiating factor (MPF), osteopontin, or fibulin-
3 are elevated in MPM compared to asbestos-exposed or secondary pleural malignancies [115–117].
SMRP has the most evidence in the context of diagnosis or disease monitoring. A meta-analysis 
reviewed 30 publications for the use of SMPR for diagnosis [116]. It showed a pooled sensitivity of 61% 
and a specificity of 87%, with and area under the curve of 0.81. However, only 16% to 40% of asbestos-
exposed individuals who develop mesothelioma will have elevated SMRP levels on follow-up. In 
addition, SMPR have been shown to positively correlate with tumor size, stage, and falling after surgery 
in patients with positive chemotherapy response [118]. The original publication on fibulin-3 showed 
intriguing diagnosis accuracy, but validation cohorts haven not confirmed these findings: sensitivity of 
100%, specificity of 94% with and AUC of 0.87 [117,119]. However, as stated in systematic review in 
2017, more data is needed and none of these markers are currently recommended in routine clinical use
[7].
Activins and follistatins
Activins are dimeric proteins that belongs to the TGF- β family [120]. They contain two β-subunits (βA, 
βB, βC, βD, and βE) generating homo- or heterodimers. The most studied and biologically active 
isoforms are activin A (βA and βA), activin B (βB and βB), and activin AB (βA and βB) [121]. Like 
other members of the TGF- β family, activin signaling is mediated through the transmembrane 
serine/theorine kinase receptor type I and II (ActRI, ActRIIA/ ActRIIB) [122]. The most common 
signaling pathway starts when activins binds to the ActRII which triggers ActRI, subsequently leading
to the phosphorylation of Smad2/3 [123]. In addition to the Smad-mediated signaling pathway, other 
Stage with prevalence (%) T-category N-catecory M-category
Stage IA (15%) T1 N0 M0
Stage IB (37%) T2, T3 N0 M0
Stage II (11%) T1, T2 N1 M0
Stage IIIA (13%)
Stage IIIB (20%)
Stage IV (4%)
T3
T1, T2, T3
T4
Any T
N1
N2
Any N
Any N
M0
M0
M0
M1
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cascades are recognized with different biological actions [15,124,125]. Activin signaling is controlled 
by several biological antagonists; inhibins, betaglycan, cripto, and BAMBI counteract activins at a cell 
membrane level, while follistatin (FS) and follistatin-like 3 (FSTL3) prevent activin signaling by binding 
and forming inactive complexes [126–128]. The ability of FS and FSTL3 to bind and neutralize activin
A is approximately 10-fold higher compared to activin B [129]. Similar to activins, FS and FSTL3 also 
antagonize other members of TGF-β family called myostatin and several bone morphogenetic proteins 
[130].
Activins were originally isolated from gonads and identified as inducers of follicle-stimulating hormone 
[121]. Now, they are known to be widely expressed throughout the body and to have many biological 
functions such as regulating reproduction and embryogenesis, cutaneous wound healing, hematopoiesis,
tissue homeostasis, hormonal secretion, immune responses, angiogenesis and to control cellular 
proliferation, differentiation, and apoptosis [131–136]. In healthy people, serum activin A levels increase
with age [137]. No differences were observed between sexes but elevated values were observed in 
women during gestation or menstrual cycles [138].
Increased activin expression has been linked with liver, pancreatic, kidney, and lung fibrosis [139–142].
A number of in vitro and clinical studies have found that activin levels are elevated during systemic 
inflammation such as septicemia, and inflammatory diseases like rheumatoid arthritis or inflammatory 
bowel diseases [132,143,144]. Activins can lead to anemia via reduced erythropoietin synthesis [145].
In addition, elevated activin A levels are measured in thyroid diseases, chronic renal failure, chronic 
obstructive pulmonary disease, and metabolic syndrome [137,146,147].
Depending on the tissue or stage of the tumor, activins can either inhibit or stimulate cell growth. For 
example, growth suppressive effects have been reported in breast, pancreatic and low-grade prostate 
cancer cells [148,149] whereas activin overexpression has been linked to more aggressive behavior in 
myeloma, high-grade prostate, lung, oral, esophageal, and colorectal cancers [150–155]. Moreover, high 
circulating activin A levels have been linked to worsened survival in myeloma, breast, prostate, lung, 
esophageal and pancreatic cancers patients [154–157]. Thus, it is postulated that activins are potent 
negative growth regulators in normal conditions and early stages of tumorigenesis, but several mutations 
in activin signaling genes leads to cancerous growth which is exerted by activins [158,159]. Furthermore, 
activins are hypothesized to indirectly contribute to cancer progression by modifying the tumor 
microenvironment through regulating angiogenesis and inflammatory responses [160].
FS was first isolated from bovine follicular fluid [126]. It is a single-chain glycosylated protein, with 
three major isoforms, FS288, FS315, and FS303 [161]. The structure of FSTL3 (also known as 
follistatin-related protein, FSRP) is similar to FS, except for the lack of one FS-domain and heparin 
binding sequence [162]. Activin regulation is the main biological function of FS and FSTL-3. 
Follistatins’ importance in embryogenesis was noted when a variety of lethal defects were observed in 
FS-knockout mice [163]. Like activins, FS and FSTL3 can have a dual role in tumorigenesis. In vitro 
studies have showed that adding FS to ovarian tumor cells slowed the growth rate of tumor cells, whereas 
prostate cell lines showed overproduction of FS which accelerated tumor growth [164]. In clinical 
studies, elevated FS or FSTL3 levels have been linked to poor survival in hepatocellular, ovarian, gastric,
and breast cancer [165,166].
Activins in MPM
An original report on activins in MPM was published in 2012, where it was found that activin subunits 
βA, βB, and βC are upregulated in MPM cell lines [11]. Activin A was overexpressed in tumor tissue 
compared to normal mesothelium, and most tumors stained IHC positive for activin A. In addition, 
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inhibition of activin A led to suppressed tumor growth. They observed no upregulation of FS or FSTL3. 
Another study found both activin A and B to be overexpressed in MPM tumor tissue and in cultured cell 
lines [10]. Soluble ActRIIB-blockage reduced migration and invasive growth via ERK or cyclin D 
pathway signaling. In contrast to activins, they found that expression of FS and FSTL3 were inconsistent 
among tumor cells, with FSTL3 levels mostly upregulated and FS downregulated. One multi-
institutional clinical study on circulating activin A in MPM has been previously published [12]. They 
collected plasma samples from 129 MPM patients, as well as 45 healthy controls and 16 non-malignant
pleuritis patients. Circulating activin A levels were elevated in MPM compared to healthy controls but 
were similar to those of pleuritis patients. In MPM patients, significant differences were reported based 
on tumor histology with the lowest values being observed in the epithelioid subtype. In addition, they 
found activin A to be positively correlated with pretreatment tumor size and low activin A levels to be 
associated with longer survival after adjustments for age, histology, sex, and TNM stage.
Activins and cancer cachexia
The international consensus report defined cancer cachexia as a multifactorial syndrome consisting of 
ongoing loss of muscle mass, with or without loss of fat mass, that cannot be fully reversed by nutritional 
support [167]. Cachexia is associated with physical impairment, reduced quality of life, impaired 
tolerance to anticancer therapy, and increased mortality. The prevalence of cachexia in advanced cancer 
patients is estimated to be 60% to 80% depending of the cancer tissue [168]. The degree of cachexia is 
defined by the degree of weight loss, symptoms and clinical signs: precachexia (weight loss <5%, early 
metabolic signs), cachexia (weight loss > 5% with or without low BMI or skeletal muscle mass) and 
refractory cachexia (preterminal cancer with active catabolism, PS score 3 or 4, and life expectancy < 3 
months) [167].
A key component in cachexia is catabolism caused by tumor- or host-mediated cytokines and systemic 
inflammation. Pro-inflammatory cytokines, such as tumor necrosis factor α, interferon-γ, interleukin (IL) 
1 or IL6, or C-reactive protein (CRP) trigger muscle wasting and are upregulated in preclinical cachexia 
models [169]. However, findings for inflammation markers in cachectic cancer patients are controversial 
and depend on tissue site and stage of the disease [170,171]. Other markers of cachexia include growth 
differentiation factor (GDF) 8 (myostatin) and 15, ghrelin, testosterone, insulin-like growth factor 1, 
zinc alpha 2-glycoprotein, leptin, and parathyroid hormone release peptide [172,173]. In addition to 
molecular mediators of cachexia, direct tumor burden, immobility, or treatments may lead to reduced 
food intake, impaired muscle mass, and weight loss [173].
The first evidence that activins play a role in cancer cachexia was found on inhibin-deficient mice, that 
developed gonadal tumors producing 10-fold activin A and B levels, which were observed to lead to
lethal wasting-syndrome [174]. Myostatin, another TGF- β protein, is predominantly secreted from 
muscle cells and acts as a negative regulator of muscle growth [175]. It shares, as well as GDF-11, a 
common signaling pathway with activins [176]. Multiple mouse models have showed that blocking 
ActRII prevented muscle wasting, and prolonged survival without affecting tumor growth or 
inflammatory cytokine levels [14]. Similar effects were seen in myostatin-deficient mice, which suggests 
that other ligands also contribute to muscle wasting [177]. Blocking of the activin/myostatin pathway 
has been studied in several phase I-II clinical trials, with positive results in muscle volume and strength 
[178]. In addition, one clinical study has compared circulating activin and myostatin levels on lung and 
colorectal cancer patients [13]. Overall, these studies have shown an association with activin levels and 
cachexia, whereas myostatin levels have been shown to correlate with muscle mass but with not 
cachexia. These observations are comparable to those obtained in animal models. 
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2.2.9 Diagnosis 
A definite diagnosis of MPM requires both morphologic and immunohistochemical (IHC) features 
suitable for MPM as well as a histopathological confirmation of invasive tumor growth into adjacent 
tissues [17]. However, in some instances, a reliable diagnosis can be achieved if clinico-radiological 
findings are consistent with MPM and with a supporting cytological sample. However, there are several 
diagnostic pitfalls in the cytological specimen, which makes cytological diagnosis less reliable [179].
Pleural effusion in MPM is often hemorrhagic or inflammatory, which might mask malignant cells. 
Obtaining a cellblock from effusion samples allows ancillary methods, such as IHC or molecular 
analysis to be done. These methods are needed to distinguish malignant from reactive mesothelial 
proliferation [180]. Once the malignant nature has been verified, the next step is to demonstrate the 
mesothelial subtype of the tumor cells, which is most often done by IHC staining (Table 2). In addition, 
the sarcomatoid mesothelioma will not exfoliate sufficient tumor components in the pleural effusion, 
which makes it impossible to diagnose solely from cytological specimen [16].
Reaching a conclusive MPM diagnosis from histological samples can also be challenging, especially 
from small biopsies. In France, a national pathologist panel reviewed over 1000 cases with initial 
mesothelioma diagnosis in 1998-2003; they confirmed the diagnosis in 67% of the cases, ruled out 13%,
and classified the rest as uncertain [55]. Similar results have been published afterwards, even if
diagnostic methods have been improved. Another study compared biopsy size with diagnosis and found 
that biopsies over 10 mm achieved definite diagnosis in 86% of cases, while those smaller than 10 mm 
were classified as definite only in 14% of cases [181]. Also, needle biopsies are associated with 
misclassification of MPM subtype in up to 44% of cases [182]. Therefore, thoracoscopy, either medical 
pleuroscopy or video-assisted thoracic surgery (VATS), is the recommended diagnostic procedure [9].
The benefits of surgical operation are direct visual observation of the pleura, improved size of the tissue 
samples, and possible pleural effusion treatment in the same procedure. The complication rate in 
diagnostic VATS is less than 10% with most reported complications being local infection, small 
hemorrhage, subcutaneous emphysema, and a mild fever [183]. In some instances, especially if 
thoracoscopy is unsuitable, either US- or CT-guided transthoracic needle biopsy can be carried out at 
the expense of the diagnostic sample size.
Histological classification of MPM is important for prognostic evaluation and treatment guidance. The
World Health Organization (WHO) released a new classification of tumors of the pleura in 2015 (Table 
3) [17]. Histologic classifications remain unchanged compared to 2004 with the following main three 
histologic subtypes being recognized: epithelioid, biphasic, and sarcomatoid [184]. Desmoplastic 
mesothelioma is a rare sarcomatoid variant, which represents approximately 2% of all MPM cases. In 
contrast, epithelioid is the most common subtype comprising approximately 60% of MPM cases [35].
Histological tumor grade describes the appearance of tumor cells and tissue under the microscope. It 
indicates the degree of tumor differentiation. Well-differentiated tumors present close to normal cells or 
tissue and tend to have more indolent behavior. Thus, the purpose of applying a grading system in MPM 
would be to allow differentiation of indolent tumors from more aggressive ones. Although there have 
been several studies regarding mesothelioma grading, to date, no uniform grading system is 
recommended by WHO or other organizations [17].
MPMs histological subtypes have a wide histopathological heterogeneity. Epithelioid MPM comprise
polygonal, oval or cuboidal tumor cells with, in general, ample cytoplasm and round nuclei with 
prominent nucleoli [16]. A variety of morphological patterns are recognized within the epithelioid
subtype, such as tubulopapillary, papillary, micropapillary, trabecular, solid, and pleomorphic patterns 
[185]. The presence or absence of mitoses, acinar structures, myxoid change, psammoma bodies,
necrosis, cytologic features (microcystic, clear cell, deciduoid, small cell) can present with various 
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degrees in epithelioid mesotheliomas [35]. The sarcomatoid subtype consists spindle-shaped (greater 
than two times in length than width) cells characterized by elongated nuclei, numerous mitosis, and 
eosinophilic cytoplasm. The histological features that can be recognized in sarcomatoid tumors include 
desmoplastic, lymphohistiocytoid, and osteoid- or chondrosarcomatous differentiation [186].
Sarcomatous tumors can also resemble other soft tissue sarcomatous elements [184]. Desmoplastic 
MPM is characterized by dense collagenized tissue separated by atypical cells in a storiform pattern
[187]. MPM is classified as biphasic (or mixed), if the tumor contains at least 10% of both epithelioid 
and sarcomatoid patterns [184].
Immunohistochemistry is used to visualize the tumors antigen expression using antibody-antigen-
interaction and it is widely used in cancer diagnostics [188]. IHC staining is an important supplementary
technique in discriminating MPM from other benign or malignant pleural diseases as well as 
differentiating MPM histological subtypes. The role of IHC depends on the morphological features of 
MPM as well as possible differential diagnosis [189–191]. When interpreting IHC-findings, both the 
localization of the stain and the number of cells staining positively are important. However, none of the 
IHC stains are diagnostic in all cases. Thus, the latest guidelines for pathological diagnosis of MPM 
suggest using panels with both positive markers for mesothelioma and markers for other malignancies 
that are typically negative for mesotheliomas [16]. The most widely used IHC-markers and their 
diagnostic prevalence are presented in Table 2. In a case with no evident discrepancies, at least two 
positive mesothelioma markers and two carcinoma markers are considered to be adequate for diagnosis. 
Additional, more specific markers, should be used when conflicting differential diagnosis are being
considered [16]. For example, the loss of BAP1 expression was investigated in a study consisting 258 
malignant effusions [192]. They reported that BAP1 protein was lost in 46 of 53 (87%) in MM and 4 of 
205 (2%) carcinoma cases yielding to sensitivity of 87% and specificity of 98%.
In addition to these classical histopathological tests, newer molecular techniques have been identified in 
order to aid diagnosis. Fluorescence in situ hybridization (FISH) assay for the p16/CDKN2A 
homozygous deletion can be used to distinguish benign from malignant pleural proliferation [180].
Micro-ribonucleic acids (miRNAs) are short non-coding RNAs that regulate essential cellular 
mechanisms post-transcriptionally [193]. In addition to their role in normal biology, their aberrant 
expression in cancers significantly contributes to malignant growth, which makes them potential 
biomarkers. Several miRNAs have been studied from pleural and tumor tissue, pleural effusion, and 
peripheral blood, and preliminary findings suggest that they might have potential diagnostic value but
more prospective validation is needed [194]. In addition, a sequential combination of binary gene 
expression ratio tests from tumor tissue was able to distinguish MPM from other common thoracic 
cancers and normal pleura as well as to identify histological subgroups in MPM [195].
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Table 2. Antibodies used in immunohistochemical staining for differential diagnosis
Type of tumor Positive markers (expression %) Reference
Epithelioid MPM Calretinin (>95)
Cytokeratin 5, or 5/6 (75-100)
WT1 (70-95)
Podoplanin, D2-40 (90-100)
[189,190]
Sarcomatoid MPM Cytokeratins (93)
Vimentin (91)
Calretinin (31)
[186]
Lung adenocarcinoma Claudin 4 (>95)
MOC31 (95-100)
CEA (80-100)
BER-EP4 (95-100)
TTF-1 (75-85)
Napsin A (80-90)
[189]
Lung squamous carcinoma
Solitary fibrous tumor
p40 or p63 (100)
Claudin 4 (95)
MOC31 (95-100)
BER-EP4 (85-100)
CD34 (95)
STAT6 (98)
[191]
[196]
WT1, Wilms tumor-1; CEA, carcinoembryonic antigen; TTF-1, thyroid transcription factor-1
2.2.10 Differential diagnosis
Differential diagnosis includes the separation of MPM from other primary pleural tumors, pleural 
metastasis, benign reactive mesothelial proliferation, inflammatory reactions, and other more indolent 
mesotheliomas [184]. In most cases, morphological features along with appropriate IHC and clinical 
behavior are sufficient for a correct diagnosis. However, in some instances, additional work-up is 
needed.
The most common differential consideration in epithelioid MPM is the metastatic non-small-cell lung
carcinoma (NSCLC). They represent approximately 40% of metastatic pleural cancers [197]. Other
common secondary malignancies of the pleura are breast carcinoma, malignant melanoma,
gastrointestinal cancers, renal cell carcinoma, and pleural dissemination of thymoma [16]. The 
sarcomatoid MPM may be difficult to distinguish from some sarcomas or other tumors with sarcomatoid 
histology [16]. In addition, the histological distinction between the desmoplastic MPM and benign 
fibrous pleuritis can be challenging.
Besides mesothelial tumors, the WHO classification of tumors of the pleura recognizes primary pleural 
mesenchymal tumors and lymphoproliferative disorders (Table 3) [184]. Mesenchymal tumors are 
further divided into three groups: fibroblastic tumors, vascular tumors, and tumors of uncertain 
differentiation. Rarely, lymphomas can arise primarily from the pleural surface [198]. Most cases are 
associated with immunosuppression or chronic pleural inflammation and they can present with no 
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evident tumor mass; the diagnosis is made with flow cytometry, molecular examination along with IHC.
More commonly, a pleural involvement can coexist with generalized hematologic malignancy [199].
The existence of an in-situ form of mesothelioma is debated. The latest pathological classification 
suggests the use of the term “atypical mesothelial hyperplasia” since there is no reliable method to 
distinguish possible in situ phase from reactive proliferation [17]. More recent expert proposal suggested 
that mesothelioma in situ could be diagnosed in the absence of clinical or radiological evidence of tumor 
with mesothelial proliferation limited to serosal surface and IHC/molecular findings consisting of MM 
[108]. In-situ MM or atypical hyperplasia may show high cellularity, numerous mitoses, necrosis, 
cytologic atypia, and formation of papillary structures [180]. The presence of invasion is the single most 
useful criteria for malignant growth. In addition, several genetic markers have been studied for 
separating benign from malignant mesothelial processes [200]. The loss of BAP1 in IHC or deletion of 
p16/CDKN2A by FISH are the most promising markers, since they have been reported only in malignant 
diseases [201]. However, the low sensitivity (approximately 50%-80% in both) and the lack of 
specificity for MPM (both can be found in other malignancies as well) needs to be considered.
The term ‘diffuse malignant mesothelioma’ is used to separate it from other distinct entities of 
mesotheliomas. Identical histopathologic, IHC, and ultrastructural features compared to diffuse MPM
have been reported in localized malignant mesothelioma (LMM) [184]. These solitary circumscribed
tumors present with profound invasion without diffuse pleural spread of the tumor. The diagnosis 
requires histology comparative with MM as well as a correlation with imaging and surgical findings to 
ensure that there is no diffuse component. Surgery can be curative in LMM, but recurrence or metastasis
can occur after resection. The largest surgically treated series published so far reported that 10 out of 21 
patients were disease-free after a median follow-up of 4.8 years (range: 1.5 to 11 years) [202]. Another
study looked at previously published LMM cases (n = 48) and reported a pooled median OS of 36 months 
with a range of 0 to 132 months [203]. Well-differentiated papillary mesothelioma (WDPM) is a rare 
variant that usually involves the peritoneum in young women [204]. When found on pleura, it is
characterized by exophytic papillary architecture with broad fibrovascular cores. They usually present 
with superficial growth with no or only minimal areas of invasion [205]. These tumors have indolent 
behavior, with a reported median OS of 74 months [204]. Adenomatoid tumors are benign mesothelial 
neoplasms that mostly arise from the genital tract but can rarely be found on pleura, peritoneum or 
pericardium [184].
 29
2.3 Survival and prognostic factors in MPM
Survival time is usually calculated either from the time of diagnosis or study enrollment until death, 
cancer recurrence or the end of study follow-up [206]. Prognostic factors are variables obtained from
the tumor or patients that are available at the time of the diagnosis. They are related with the natural 
history of the disease, in the absence of therapy, and are associated with overall survival (OS) or disease-
free survival (DFS). Prognostic factors may be needed in order to choose the appropriate treatment 
strategy for individual patients as well as to design or conduct a clinical trial [207]. In most malignant 
tumors, prognosis is influenced by a variety of variables called covariates. In order to determine if one 
factor affects prognosis independently of others, multivariate analyses are performed.
2.3.1 Statistical survival analyses
The most common endpoints in cancer trials are OS, DFS and progression-free survival (PFS), response 
rate (RR), and quality of life (QoL). Survival analyses are usually performed either by univariate cox 
regression or Kaplan-Meier method, which provides a visual cumulative survival probability curve
[208]. The comparison between different survival curves is usually tested by log rank test, which weighs
the effects of differences observed throughout follow-up [208]. The cox proportional hazards model is 
the most commonly used multivariate analysis, which is used to adjust for one or more covariates [209].
Survival data is usually presented as hazard ratios (HRs), which reflects to event rate at the given time,
with 95% confidence intervals (CIs), [206].
2.3.2 Mortality 
Following the rise in the incidence of MPM, age-adjusted mortality rates are estimated to have increased 
by 5.4% per year worldwide between 1994 and 2008. Analyses from the WHO mortality database
estimated over 38,000 annual deaths globally [210]. The overall median survival reported from large 
international register studies varies from 9 to 12 months [20,211]. Likewise, the median survival of 
Finnish patients was 9.7 months in the FCR analyses [19].
Table 3. World Health Organization classification of tumors of the pleura [17]
Mesothelial tumors Lymphoproliferative disorders Mesenchymal tumors
Diffuse malignant mesothelioma Primary effusion lymphoma Vascular tumors
   Epithelioid mesothelioma Diffuse large B-cell lymphoma 
associated with chronic inflammation
   Angiosarcoma
   Sarcomatoid mesothelioma    Epithelioid hemangioendothelioma
      Desmoplastic mesothelioma Fibroblastic tumors
   Biphasic mesothelioma    Solitary fibrous tumor
Localized malignant mesothelioma       Malignant solitary fibrous tumor
   Epithelioid mesothelioma    Calcifying fibrous tumor
   Sarcomatoid mesothelioma    Desmoid-type fibromatosis
   Biphasic mesothelioma Uncertain differentiation
Well-differentiated papillary mesothelioma    Synovial sarcoma
Adenomatoid tumor    Desmoplastic round cell tumor
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2.3.3 Clinical prognostic factors
Table 4 reviews studies considering clinical prognostic factors. Different study designs and inclusion 
criteria need to be taken account when assessing survival and prognosis. The most consistent
independent markers of good prognosis in large population-based registry studies are young age, 
epithelioid histology, female sex, and good performance status (PS) [20,23,106]. After multivariate 
adjustments, many studies have shown that the presence of symptoms such as chest pain or weight loss 
are associated with a higher mortality [212]. Prior asbestos exposure is considered more of a risk factor 
than a prognostic factor, although some studies have reported better prognosis for patients with no or 
minimal asbestos exposure [213]. Similarly, one study found a 2.6-fold longer survival in patients who 
developed MPM after lymphoma-related radiation therapy, when compared to asbestos-related patients 
[214].
In surgically treated patients, predictors of longer survival are epithelioid subtype, adjuvant 
chemotherapy, negative surgical resection margins, and absence of lymph node metastasis [104,215].
Moreover, in a three-year survival analysis after following curative intent surgery, clinicopathological 
features associated with prolonged survival were young age, female sex, epithelioid subtype, normal 
preoperative white-blood cell, hemoglobin, and platelet counts [22].
Several prognostic scores have been created by combining different variables to give a better survival 
estimation [212,216,217]. The best validated ones are from the Cancer and Leukemia Group B and 
European Organization for Research and Treatment of Cancer, both of which were produced from phase 
II clinical trials, which limits the generalizability to the overall MPM population. In contrast, one study 
reported an unselected MPM cohort of 482 patients and developed a prognostic tree, which was validated 
in a separate cohort [212]. They showed that the combination of weight loss, ECOG PS, Hb, albumin, 
and histology was able to stratify patients into four different risk groups. The single strongest prognostic 
variable was weight loss, and the best prognosis was found for patients with no weight loss, Hb over 153 
g/l, and normal albumin levels (group 1; median survival of 34 months comparing to 7.4 months in group 
4). The same prognostic model could also stratify surgically treated patients into risk groups according 
to survival: median survival in group 1 was 82.5 months compared to 22.2 months in group 4 [218]. A
prognostic score has also been proposed for patients undergoing multimodality treatment [219] and it
includes pre-chemotherapy tumor volume, progressive disease after induction chemotherapy, pre-
chemotherapy CRP, and histological subtype. The original cohort reported a median survival of 34 
months on patients with 0-points, compared to 4 months in patients with 4-points – these findings have 
been also externally validated in an independent cohort.
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Table 4. Review of studies on clinical prognostic factors in MPM
Ref, reference; NLCA, national lung cancer audit; MPM, malignant pleural mesothelioma; PS, performance score; SEER, surveillance, 
epidemiology, and end results; IASLC, international association for the study of lung cancer; NA, non-available; TNM, tumor node 
metastasis; PLT, platelet count; WBC, white blood cell count; CCI, Charlson comorbidity index; ASA-score, American Society of 
Anesthesiologists; BMI, body mass index; KPS, Karnofski performance score
Country [Ref] Published / 
Data collected
(years)
Population: 
N / male % / 
age(years)
Study design Inclusion criteria OS 
(months)
Independent prognostic factors 
(comparison variable)
Effect size (95% 
CI or p-value)
UK [20] 2015/
2008-2012
8740 / 83% / 
73
Prospective 
follow-up
cohort, NLCA 
Population-based: 
Histopathological or 
clinic-radiological 
proven MPM  
9.5 PS 4 (PS 0)
Sarcomatoid (epithelioid)
6.49 (5.24-8.05)
2.40 (2.16-2.70)
USA [23] 2010/
1973-2006
9701 / 81% / 
72
Retrospective 
follow-up
cohort, SEER 
registry
Population-based:  
MPM diagnosis
12 Age (cont.)
Sex, male (female)
Non-epithelioid (epithelioid)
High tumor grade (low)
Local SEER stage (distant)
Surgery, yes (no)
1.02 (1.01-1.04)
1.32 (1.01-1.72)
1.15 (0.86-1.53)
1.55 (1.36-1.76)
0.84 (0.55-1.29)
0.62 (0.48-0.79)
International 
[106]
2014/
1995-2009
2141 /80% /
50-65
Retrospective
follow-up
cohort, 
IASLC 
database
Diagnosis of MPM 
with complete dataset 
available 
NA pTNM stage IV (stage I)
Non-epithelioid (epithelioid)
Sex, male (female)
Age > 50 (age < 50)
Palliative surgery (radical)
Adjuvant treatment, no (yes)
PLT > 400 (< 400) x 109/l
WBC > 15.5 (<15.5) x 109/l
2.49 (0.0001)
1.80 (<0.001)
1.70 (0.0006)
1.61 (0.0120)
1.67 (0.0008)
1.70 (0.0002)
1.50 (0.0004)
2.39 (0.0007)
International 
[220]
2009/     1984-
2003
523 /83%    / 
58
Composite 
analysis of 10 
prospective 
phase II trials 
Histologically or 
cytologically proven 
MPM, chemotherapy 
or radiotherapy naïve, 
PS 0-2
9.1 PS 2 (PS 0)
Non-epithelioid (epithelioid)
cTNM stage IV (stage I-III)
2.89 (NA)
1.60 (1.20-1.71)
1.49 (1.17-1.91)
Italy [221] 2014/     2005-
2011
241 /64%    / 
75
Retrospective 
case series, 
multicenter
All patients aged over 
70 years with MPM 
diagnosis
11.4 Non-epithelioid (epithelioid)
Age > 75 (age < 75)
cTNM stage III-IV (stage I-II)
CCI > 1 (CCI 0)
2.32 (1.66-3.23)
1.44 (1.08-1.93)
1.47 (1.09-1.98)
1.38 (1.02-1.85)
USA [222] 2007/     1990-
2005
945 /80%    / 
66
Retrospective 
case series, 
single center
Biopsy-proven MPM 12.5 Surgical treatment, yes (no)
Non-smokers (smokers)
Sex, female (male)
Chest pain, no (yes)
Epithelioid (non-epithelioid)
Laterality, left (right)
0.75 (0.62-0.91)
0.77 (0.61-0.97)
0.63 (0.51-0.77)
0.77 (0.69-0.91)
0.59 (0.46-0.71)
0.84 (0.72-0.98)
USA [223] 2013/    2000-
2010
170 /71%    / 
73
Prospective, 
case series, 
single center
Surgically obtained 
histologically proven 
MPM
12.0 Non-epithelioid (epithelioid)
Age (cont.)
CRP, 3-50 (CRP <3) mg/L
WBC > 12 (WBC<12) x 109/l
2.76 (1.50-5.08)
1.05 (1.01-1.08)
2.28 (1.18-4.42)
2.28 (1.22-4.25)
Turkey [224] 2009/     1991-
2008
235 /NA      / 
NA
Retrospective, 
case-control 
according to 
treatment 
schedule, 
single center
Diagnosis of MPM 10.0 1)BSC group: 
KPS >70 (KPS<70)
Non-epithelioid (epithelioid)
TNM stage III-IV (stage I-II)
LDH >500 (LDH <500) IU-1
2)Chemotherapy group: 
KPS >70 (KPS <70)
3) Surgical group: 
Laterality, right (left)
Non-epithelioid (epithelioid)
3.83 (1.98-7.42)
1.86 (1.06-3.26)
2.28 (1.24-4.17)
2.21 (1.19-4.09)
4.78 (2.73-8.37)
4.53 (1.23-16.7)
4.55 (1.02-20.3)
USA [104] 1998/     1980-
1997
183 / 77%   / 
57
Retrospective 
case series, 
single center
Trimodally treated 
histologically proven 
MPM
19.0 Non-epithelioid (epithelioid)
Positive resection margins (neg.) 
Positive extra pleural node 
metastasis (neg.)
3.0 (2.0-4.5)        
1.7 (1.2-2.6)        
2.0 (1.3-3.2)
UK [215] 2014/     2000-
2012
252 / 86%   / 
59
Retrospective 
case series, 
single center
Surgically treated 
epithelioid/biphasic, 
survival longer than 
90 days
18.2 Age < 60 (age >60)
Epithelioid (biphasic)
Negative node metastasis (pos.)
Chemotherapy, no (yes)
0.70 (0.51-0.94)
0.56 (0.39-0.79)
0.67 (0.49-0.90)
1.90 (1.39-2.54)
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2.3.4 Somatic and germline mutations 
The prognostic role of the most common mutation in MPM, BAP1, is controversial. One study found 
that loss of BAP1 detected by IHC was an independent negative prognostic factor after multivariate 
adjustments, but other reports have not found clear survival differences [76,225]. Deletion of the
CKDN2A gene, which encodes the well-established tumor suppressor p16, is another frequently 
reported genetic abnormality, and homozygous deletion detected by FISH or loss of expression 
detected by IHC, have both been associated with a poor survival [226]. In addition to these two most 
common mutations, several other genes are overexpressed in MPM with different prognostic
characteristics and possible therapeutic implications [79]. A four-gene ratio test has been created with 
a good predictive value for OS in surgically treated patients: “good risk” patients had median OS of 
16.8 months compared to 9.5 months in “poor risk” patients [227]. In addition, multiplatform 
molecular profiling has been used to form different clusters with prognostic significance 
independently of histological subtype or CKDN2A status [76]. The poor prognosis cluster had a high 
score for epithelial-mesenchymal transition, enrichment of LATS2 and CKDN2A mutations, and 
upregulation of the PI3K and mTOR signaling pathways. Similarly, four molecular clusters
established via RNA-sequencing, namely sarcomatoid, epithelioid, biphasic-epithelioid, and 
biphasic-sarcomatoid have been identified [78]. These genomic clusters correlated with survival
better than traditional histological subclassifications. Interestingly, only 38% of epithelioid 
histological tumors were defined as genetically epithelioid, which underlies the heterogeneity within 
the MPM tumors. Patients with epithelioid histology and epithelioid genetic cluster had better 
survival compared to those with epithelioid histology and other clusters (HR 2.5, 95% CI 1.6-3.8). 
The original finding that patients with germline BAP1 mutation have a better prognosis derives from
a series of 23 MM patients with a median survival of 5 years [228]. Similarly, another study reported 
a prolonged median survival of 9 years in 36 patients with germline mutations other than BAP1.
Another study evaluated the prognostic value of germline mutations in a cohort of 239 MPM patients
and found an almost four times higher median survival in patients with a germline mutation [229].
Moreover, a recent study observed that the loss-of-function mutation in any DNA repair gene was 
associated with improved OS after platinum-based chemotherapy [229].  
MicroRNAs are involved in numerous cellular processes and may behave either as tumor suppressor 
or oncogene. Several different circulative miRNAs with different prognostic utility have been 
identified in MPM. Kirschner et al. constructed a score of six microRNAs that was able to predict
over 20 months OS with an accuracy of 92% in patients with surgical treatment [230]. Moreover, a 
different miRNA signature could predict histological subtype with correlation with survival [231].
However, additional research is needed prior to clinical use, since most of the data is based on small 
sample sizes or in vitro findings.
2.3.5 Prognostic circulating biomarkers 
Several routinely used laboratory measurements are reported to have a prognostic role in MPM. The 
best validated ones include elevated numbers of WBC, platelet counts, CRP levels, lactate 
dehydrogenase levels as well as high neutrophil to lymphocyte ratio, whereas low levels of albumin 
and hemoglobin (Hb) are associated with worse survival [216,217,232]. These non-specific 
parameters are likely to reflect disease activity and systemic inflammation. However, none of these 
are specific to MPM, and could simply relate to malignancy, chronic disease, or infection.
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Several novel circulating biomarkers have been evaluated in an attempt to stratify MPM prognosis.
The most extensively studied markers are glycoproteins mesothelin/SMRP, osteopontin, and fibulin-
3 as well as megakaryocyte potentiating factor. Some studies have identified prognostic value for all 
of them, while others have shown no benefit [233–237]. A systematic review published in 2017
identified 45 studies on circulating biomarkers [7]. Due to considerable variation in study design, 
patient selection and treatment regimen, the authors concluded that none of them should be used for 
clinical use before a large-scale high-quality prognostic validation.
2.3.6 Radiological prognostic factors
The available imaging techniques, especially CT, usually underestimate the true extent of MPM. 
Despite inaccuracies in clinical TNM staging, it has been proven to be an independent prognostic 
marker in several studies [220,221]. The IASLC staging project reported a median OS of 21, 19, 14, 
and 10 months in MPM patient with stage I, II, III, and IV, respectively [106]. However, several other 
radiological methods have been proposed to replace or supplement the TNM T-category. CT-derived 
tumor volume (TV) has been shown to predict survival after multivariate adjustments [238]. A recent 
publication studied the tumor extension, i.e. number of tumor sites (graded one to three), and found 
that it predicted survival as well as clinical TNM stage and TV [239]. In addition, maximal tumor 
thickness calculating from axial CT-scans correlated with survival in surgically treated patients [6].
Also PET-CT has been used to assess prognosis: several studies have found that increased levels of 
SUVmax are related with a poor prognosis [240,241]. This could be driven by different metabolic 
activity in histologic subtypes; epithelioid tumors being less metabolically active than non-epithelioid
tumors. In addition, two studies combined TV with metabolic information, namely total glycolytic 
volume (TGV) [242,243], and showed that TGV was superior to clinical TNM stage in predicting 
survival. 
2.3.7 Histological prognostic factors and tumor immunogenity
The major histologic subtypes are the most important prognostic factors recognized by the WHO 
classifications of tumors of the pleura [184]. A large retrospective analysis including 4207 patients 
(68% epithelioid, 18% sarcomatoid, 13% biphasic) showed a median OS of 14.4 months in 
epithelioid, 9.5 months in biphasic and 5.3 months in sarcomatoid subtypes, respectively [25].
Desmoplastic MPM, a rare variant of sarcomatoid, have similar prognosis than pure sarcomatoid 
subtype [186].
Several prognostic factors have been studied within the epithelioid subtype, since it is the most 
common subtype and has the best prognosis. The prognostic importance of morphological growth 
patterns are well recognized tubulopapillary or trabecular (median OS 17.9-24.9 months) tumors have 
a more favorable prognosis compared to pleomorphic, solid or micropapillary tumors (median OS 
8.1-15.8 months) [185,244]. Another study evaluated the prognostic impact of several nuclear 
features [245]. Multivariate analyses found that mitotic count and nuclear atypia had an independent 
prognostic impact. Subsequently, three-tier nuclear grading scores were proposed: grade I (median 
OS 28 months), grade II (median OS 14 months), and grade III (median OS 5 months). These findings 
have been since validated in a multi-institutional study [246]. They also suggested that adding 
necrosis to nuclear grade would further stratify the prognosis [246]. In addition, since both the 
presence of necrosis and a large number of mitotic cells were independent negative prognostic 
markers, a mitosis-necrosis score was proposed. Other reported markers of bad prognosis are the 
presence of lymphatic or vascular invasion, atypical mitoses, and the absence of myxoid stroma
[245,247].
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The role of immune cells within the tumor microenvironment has gained more attention after the 
emergence of recent immunotherapy agents in various cancers. The tumor microenvironment in MPM 
is composed of a mixture of stromal, endothelial, and immune cells (such as T-regulatory, 
granulocytic, and monocytic myeloid-derived suppressor cells and M2-polarized tumor associated 
macrophages) and is generally highly immunosuppressive [248]. This immunosuppressive state helps 
the tumor to evade the host immune system. Several studies have identified different distributions of 
immune cells within the tumor tissue or pleural effusion, which is explained by the ongoing dynamic 
changes in the immunoenvironment. The prognostic role of expression of programmed death ligand 
1 (PD-L1), which inhibits T-cell function via PD-1 and is one of the targets of checkpoint inhibitors, 
was retrospectively studied in tumor samples from patients enrolled in a clinical phase three trial 
[249]. Results showed that out of 214 tumor samples 36% were positive for PD-L1 with 65% of them 
expressing over 50% of PD-L1. PD-L1 staining was a significantly negative prognostic factor in 
univariate survival analyses; with a cut-off 50%, the median survival was 10.5 months in PD-L1 
“high” and 19.3 months in PD-L1 “low” cases. Another study found that patients with PD-L1 positive 
tumors had a median OS of 4.8 months compared to 16.3 months in those with PD-L1 negative tumors 
[250]. One study found that tumor microenvironment enriched with T-lymphocytes and macrophages
was associated with higher PD-L1 expression on tumor cells and with aggressive histopathological 
features, leading to worse prognosis [251]. In addition, the prognostic value of semi-quantitative 
assessment of inflammatory invading cells either in stroma or tumor was assessed in epithelioid MPM
[252]. Results showed that chronic inflammation in the stroma, but not in the tumor, was an 
independent positive predictor of survival. Similarly, an improved outcome was observed in 
surgically treated patients with higher intra-tumor infiltration by cytotoxic CD8+ T-cells [253]. On 
the contrary, Salaroglio et al. found no association of survival with CD8+ T-cells but reported that 
high amount of intra-tumor T-regulatory cells and myeloid-driven suppressor cells were negative 
prognostic factors [254]. Several larger prospective studies are now ongoing in an attempt to
systematically characterize the clinical utility of the immune microenvironment in MPM.
2.4 Treatment of MPM
The most recent treatment guidelines for MPM are the 2018 British Thoracic Society (BTS) and the
2018 American Society of Clinical Oncology (ASCO) guidelines [8,9]. In addition, the new edition 
of the joint guideline by European Respiratory Society (ERS) and European Society of Thoracic 
Surgeons (ESTS) was presented in the 29th annual ERS congress [255].
2.4.1 Surgical treatment
Surgical intervention may be needed for diagnosis, staging, and treatment of MPM patients. The aim 
of surgical treatment is either palliative symptom relief or an intent for local control by complete 
macroscopical resection, defined as a removal of all grossly visible and palpable tumor (R1 resection)
[256]. It is practically impossible to achieve microscopically free resection (R0) margins due to 
anatomical circumstances. Thus, surgery alone cannot cure MPM, which have led to search for 
adjuvant therapies after surgery [257]. Surgical options can be divided into palliative partial 
pleurectomy (partial removal of parietal or visceral pleura for diagnostic or palliative purposes),
curative intent pleurectomy/decortication (P/D, parietal and visceral pleurectomy to remove all gross 
tumor), extended P/D (parietal and visceral pleurectomy with resection of the diaphragm and 
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pericardium if required), or extrapleural pneumonectomy (EPP, en bloc resection of the parietal 
pleura, pericardium, diaphragm, lung, and visceral pleura) [258]. Due to variability in the types of 
operations that are performed, a taskforce report was published in 2019 in order to standardize 
surgical-based treatments [257]. After surgery, local, ipsilateral hemithorax is the most common site 
of recurrence, while recurrence in contralateral lung, abdomen, or more distant sites can also occur
[259]. In these cases, second line surgical resection can be an option for selected patients but the 
evidence to support this is lacking.
Radical surgery with curative intent was first introduced by Butchart in the 1970s, and, currently, the
two main options are EPP or (extended) P/D [103]. In general, only patients with low tumor burden,
epithelioid histology, good PS, absence of extrathoracic and lymph node involvement, and without
significant comorbidities are considered candidates for curative intent surgery [260]. Most of the 
surgical literature is based on uncontrolled case series or registry studies that are prone to both
publication and selection bias. In addition, the lack of standardization of adjuvant therapies, usually 
combined with surgery, makes interpretation of the efficacy of single treatment modality challenging. 
The reported median survival in the two most radical procedures varies from 14 to 25 months [241].
A meta-analysis including 22 retrospective studies and 2 small early-phase studies compared these 
two radical surgical techniques and found only modest, non-significant, differences on 2-year survival
[258]. However, P/D had an associated 2.5-fold lower perioperatively mortality. Similarly, morbidity 
is constantly lower and QoL is higher in patients treated with P/D when compared to EPP [261]. The 
advantages of EPP compared to P/D are a more standardized procedure, simplified use of adjuvant 
radiation, and a smaller amount of microscopic disease after the operation. The most frequent
complications after these radical operations are cardiac arrhythmias, local and systemic infections,
venous thrombosis, bronchopleural fistulas, gastrointestinal complications, and acute respiratory 
distress syndrome (ARDS) [258].
Mesothelioma and Radical Surgery (MARS) trial was the first multicenter randomized controlled 
trial that was designed to assess if it is possible to randomize patients into EPP or no surgery in a 
multimodality setting. The initial screening ended with 257 potentially eligible patients, out of which 
50 were subsequently randomly assigned to either EPP or no EPP after induction chemotherapy
[262]. Even though the trial was not designed and it did not have power to analyze survival 
differences, it reported a shorter survival in patients with surgery (median OS 14.4 versus 19.5
months; HR 1.90, 95% CI 0.92-3.93, p = 0.082; adjusted HR 2.75, 95% CI 1.21-6.26, p = 0.016).
Similarly, median QoL scores were consistently lower in surgically treated patients, although the 
difference was not significant. The authors concluded that radical surgery in the form of EPP within 
multimodality treatment offers no benefits and possibly causes harm to patients, and thus it is not 
feasible to conduct a larger study [263]. However, the study has been heavily criticized for its low 
sample size, lack of chemotherapy standardization, poor protocol compliance, and higher 
postoperative mortality and morbidity in EPP patients compared to previous studies [264].
Nonetheless, many centers have shifted from EPP to less arduous lung sparing surgery during the last 
decade [18].
The lack of good quality trials makes the role, extent, and procedures of radical surgery controversial 
and different guidelines have different suggestions: the BTS and ERS/ESTS guidelines suggest to
only perform curative intent surgery in clinical trials, whereas ASCO guidelines made a strong 
recommendation for maximal macroscopic resection in highly selected patients, preferably in the 
context of multimodality treatment performed in centers of excellence [8,9]. To overcome the lack of 
high-quality surgical evidence, MARS2 randomized clinical trial is now ongoing. They aim to 
compare extended P/D against no surgical treatment in combination with pemetrexed/cisplatin 
chemotherapy [265].
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2.4.2 Intracavitary therapies
Additional intraoperative loco-regional treatments aim to improve the local effect of surgery. Adding
cytotoxic regimen directly to the tumor surface minimizes systemic adverse effects. The first reports 
using intracavitary chemotherapy are from 1980s in the field of abdominal surgery, while their use 
was adopted in the MPM in the 1990s [266]. Different intracavitary chemotherapy regimens have 
been used with an addition of hyperthermia, which has been shown to improve in vitro cytotoxicity 
with good tolerability [267]. Sugarbaker et al. retrospectively compared the outcomes of patients 
treated with either EPP or P/D with or without intracavital heated chemotherapy and found 
significantly better survival in patients who received additional local therapy (35 versus 23 months) 
[268]. In addition, clinical benefits with low toxicities have been published in early phase studies
using local oncolytic virus therapy, antiseptic povidone-iodine, photodynamic therapy, direct 
cytokine-mediated immunotherapies, gene-mediated cytotoxic immunotherapies, and chimeric 
antigen receptor T-cell therapy [269–273]. However, more clinical studies are needed before adapting
them for clinical use.
2.4.3 Systemic therapies
The standard first line of treatment in surgically unfit MPM patients is a combination of antifolate 
(pemetrexed/raltitrexed) and platinum (cisplatin/carboplatin) chemotherapy [8]. Its efficacy was 
proved in a randomized phase III trial where a median OS of 12.1 months was observed in 
combination chemotherapy compared to 9.3 months OS with single cisplatin treatment [274].
Similarly, they reported improved QoL in the combination therapy arm. A subsequent nonrandomized 
open-label study, with over 1700 patients, confirmed similar efficacy with pemetrexed-carpolatin
than with pemetrexed-cisplatin [275]. The combination of pemetrexed-cisplatin demonstrated a RR 
of 26.3% compared to 21.7% for the pemetrexed-carboplatin group. Pemetrexed maintenance therapy 
after 4 to 6 cycles of combination therapy has been studied in a phase II randomized trial of 49 patients 
[276]. The study reported no difference in PFS (HR 0.99, 95% CI 0.51-1.90) or OS (HR 0.86, 95% 
CI 0.44-1.71). The addition of anti-VEGF, bevacizumab, to the combination chemotherapy for 4 to 6 
cycles followed by bevacizumab maintenance therapy increased the median survival by 2.7 months
(HR 0.77, 95% CI 0.62-0.95) at the expense of increased toxicities, treatment cessations, and 
treatment costs [277]. However, other clinical trials have failed to demonstrate any clinical benefit 
from anti-angiogenetic drugs, which explains why this druggable pathway have failed to translate 
into wide general practice [278,279]. In patients with multiple comorbidities or frailty, single agents 
of pemetrexed, gemcitabine or vinorelbine could be offered even though the response rates are lower 
than with combination therapy [8,9]. Clinical trials on systemic chemotherapy have not shown big 
differences in efficacy among histological subtypes and thus similar approaches should be used 
regardless of the histology.
There is no recommended standard second line therapy for patients who have progressed after 
platinum-antifolate chemotherapy. Either single-chemotherapy, or retreatment with pemetrexed-
based chemotherapy can be used in patients who achieved durable disease control in the first-line
setting [8]. The emergence of immune checkpoint inhibitors has revolutionized treatments in many 
types of cancer, such as NSCLC. In MPM, there have been a several phase I-II studies with ongoing 
phase III trials. Preliminary results on single immunotherapy agents have shown some antitumor 
activity, but these results indicate that different combinations are needed to enhance the effects of 
treatment [280]. For example, the initial observation on pembrolizumab in PD-L1 positive previously 
treated patients showed 20% RR with 12 months median duration of response, which is comparable 
to RR of 24% and 7-months median duration of response in patients treated with another anti-PD-1
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drug, nivolumab [281,282]. However, these original findings were not confirmed in a multicenter
randomized phase III trial on 144 MPM patients, where the efficacy of pembrolizumab was tested
against the investigators choice second line chemotherapy [283]. They found improved RR with 
pembrolizumab (22% versus 6%, p = 0.004) but no differences in PFS (HR 1.06, p = 0.760) or OS in 
PD-L1 positive (HR 1.47, p = 0.320) or negative (HR 0.72, p = 0.530) patients. Similarly, anti-CTLA4 
antibody tremelimumab failed to show improved outcome in second line setting, when tested against 
placebo in a large (n = 571) multicenter randomized phase II trial (HR for mOS 0.92, 95% CI 0.76-
1.12) [284]. In contrast, MAPS2 trial was a multicenter randomized phase II trial comparing PD-1
antibody nivolumab either alone or in combination with CTLA-4 antibody ipilimumab [285]. Both 
regimens showed anti-tumor activity with 12-week disease control achieved in 44% of cases leading 
to a median OS of 11.9 months in nivolumab group and 50% and 15.9 months in the combination 
group, respectively. Similarly, the combination of tremelimumab and durvalumab met phase 2 trial’s
primary endpoint with 65% disease control rate, leading to PFS of 8.0 months (95% CI 6.7-9.3) and 
median OS of 16.6 months (95% CI 13.1-20.1) [286].  These studied have showed comparable 
autoimmune toxicities compared to NSCLC studies. In addition, both objective and prolonged 
responses were seen in every histological subtype. To date, ERS/ESTS and BTS guidelines suggest 
waiting for ongoing phase III trials, while some other countries support using these regimen as a
second line treatment [9,280].
Among immunotherapies, other novel treatments that have showed positive responses in early phase 
studies include different cell-based therapies (e.g. targeting microRNAs, dendrite cells or 
mesothelin), vaccine therapies, diverse tyrosine kinase inhibitors, and arginine deprivation in 
arginosuccinate synthetase 1-deficient tumors [287–291]. The benefit of the latter has been shown
mainly in non-epithelioid patients, which differs from other available therapies. Tumor Treating 
Fields is a novel portable device that delivers specific electric frequency which interferes with cancer 
cell proliferation. It has shown promising antiproliferation effect on mesothelioma cells in vitro as 
well as median OS of 18.2 months, when combined with chemotherapy in a single arm phase II study 
[292]. In addition, comprehensive understanding of the mutational and transcriptomic landscape of 
MPM has unveiled possible druggable pathways in ongoing clinical trials [293].
2.4.4 Radiation therapy
The rationale for using radiation therapy (RT) in MPM is based on in vitro sensitivity studies and 
animal models. Radiation therapy has been traditionally used for palliation, prevention for procedure 
tract metastasis, or as a (neo)adjuvant with surgical resection [294]. The role of high-dose RT has 
been usually studied as part of a multimodality treatment, which makes the interpretation of its
singular benefits difficult. Treating the entire pleura requires a large radiation field, which increases 
the risks of toxicity [295]. Thus, novel techniques such as intensity-modulated radiation therapy 
(IMRT) have been studied as it allows higher radiation doses to the tumor while simultaneously 
sparing normal tissues. Disadvantages include dose inhomogeneity and radiation into the contralateral 
lung, which can lead to challenging lung complications, especially after EPP when the patient only
has one remaining lung [296]. Most severe RT-related adverse effects include radiation pneumonitis,
nausea, dyspnea, cough, fatigue, pericarditis, vomiting, esophagus or skin irritation [294,297]. Most 
of the side effects are mild grade I-II and their incidences is highly depending on dose and treatment 
regimen. There is no clear consensus on which modalities, dose, or fractionation should be used. 
Therefore, guidelines on role of RT differ: ERS/ESTS suggest using RT after P/D or EPP only within 
the context of clinical trials, BTS do not recommend RT other than for pain relief, whereas ASCO 
suggest using either neoadjuvant or adjuvant RT in the context of multimodality treatment, preferably 
in centers of excellence [8,9].
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A population based study from the Surveillance, Epidemiology, and End Results (SEER) database 
included 14,228 patients with mesothelioma [298]. They found no survival benefit when they 
compared outcomes of patients who received surgery alone to those who received it in combination 
with RT. The role of postoperative RT has been evaluated in one international phase II study, where 
151 patients were randomized into either adjuvant RT or no RT after neoadjuvant chemotherapy and 
EPP [299]. However, due to problems in recruiting and a high drop-out rate, only 23 patients
completed the RT-arm as planned. They found no clear benefit from postoperative RT in relapse-free 
time or OS, but the adverse effects were significantly higher in the RT group. These findings have 
been criticized due to the many limitations of the trial’s design and conduct [300]. In contrast to these 
two studies, several non-randomized studies have found that postoperative RT is feasible and shows 
a marked reduction in locoregional recurrence mainly using different techniques [295,297]. For 
example, Kostron et al. reported that the addition of adjuvant RT after EPP resulted in significantly 
less loco-regional recurrence (19% versus 47%; p = 0.003) [259]. Concurrently, the distant metastases 
occurred more frequently (36% versus 13%; p = 0.008), and there was no significant impact on 
survival. More recently, a phase III randomized trial compared the outcomes of patients treated with 
radical hemithoracic RT versus standard palliative RT after lung-sparing surgery and chemotherapy
[301]. The long-term results are awaited but preliminary results indicated that more radical RT led to
an improved 2-year survival rate of 58% compared to 28% in the standard RT arm, although this 
occured at the expense of increased toxicity rates.
MPM can spread through previous procedure tracts resulting in painful metastases. One small
randomized study consisting of 40 patients found a significant benefit from prophylactic RT, while 
two more comprehensive and recent randomized phase III trials found no differences in the incidence 
of procedure tract metastasis [37,302,303]. Moreover, they reported no benefit in QoL, symptom 
control or survival. Even though the RT doses were small, skin related side effects occurred in 
approximately half of the patients. In 2018, these results were confirmed in a systemic review and 
meta-analysis, which included five prospective randomized controlled trials [304]. Thus, prophylactic 
RT is not generally recommended, while RT is an effective option if a procedure tract metastasis 
already exists [8,9].
2.4.5 Multimodality treatment
The observation that even the most radical surgery typically results in local recurrence lead to the
addition of adjuvant therapies. Multimodality treatment refers to a combination of chemotherapy and 
RT with radical surgery. Both adjunctive therapies can be used either pre- or postoperatively [18]. A
number of non-randomized clinical trials have shown that multimodal treatment is feasible in selected 
groups of patients. The analysis of 3101 patients from the IASLC database showed superior OS for 
patients who received multimodality therapy, compared to patients with only curative-intent surgery 
(20 months versus 11 months) [113]. A systematic review on multimodality treatment including 16 
studies was conducted in 2012 [21]. This review included five prospective studies with reported mOS 
ranged from 14.4 to 25.5 months in the intention-to-treat analysis.  When all studies were combined,
DFS ranged from 10 to 16.3 months, perioperative mortality from 0 to 12.5%, and morbidity from 50 
to 82.6%. The authors concluded that multimodality treatment may offer acceptable perioperative 
outcomes and long-term survival in selected patients treated in specialized centers. However, due to
non-standardized treatment regimens, and the absence of good quality clinical trials, there are
uncertainties about the right therapeutic protocol for individual patients.
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2.4.6 Palliative treatment
Palliative treatment is designed to relieve symptoms, reduce treatment related side effects, and 
improve QoL in patients with life-threating diseases and their families. Palliative care is given 
simultaneously with other cancer treatments from diagnosis to the end of life. In contrast to many
other malignancies, a recent randomized study did not find clear benefit of early palliative care 
implementation in MPM [305].
Dyspnea is the most common symptom in MPM and is mainly due to recurrent pleural effusion. 
Therapeutic options include repetitive thoracentesis, indwelling pleural catheters, pleurodesis via talc 
slurry or poudrage, and palliative surgery. There were no differences in patient-reported dyspnea or 
QoL, when indwelling pleural catheter was tested against talc slurry in a randomized study of 106
malignant pleural effusion patients (approximately 10% of MPM) [306]. Palliative surgery should be 
considered in eligible and symptomatic patients who do not respond to conventional conservative 
treatments. One open-label randomized controlled trial has evaluated the role of palliative surgery on 
symptoms and pleural effusion [307]. It compared palliative partial pleurectomy by VATS to talc 
pleurodesis. They found no survival benefit with surgery at 12 months but pleural effusion control 
and QoL improved with surgery at the expense of increased complications, costs, and hospital stay.
The authors concluded that talc pleurodesis is the preferred method, but palliative surgery remains an 
option for certain patients. Moreover, palliative pleurectomy can free entrapped lung with 
symptomatic improvements [308].
Pain in MPM patients can be due to previous treatments or locoregional tumor invasion into adjacent 
structures. Palliative RT is an effective option to relieve pain, while it can also be used to resolve 
hemoptysis, prevent spinal cord compromise, and improve cough [294]. In pain relief, most of the 
evidence comes from retrospective series, while two small prospective trials have been conducted 
with reported pain relief in 47% and 68% of patients with minimal improvements in QoL but no 
significant side effects [309,310]. The prospective studies reported no significant differences between 
histological subtypes in terms of response. The recommended palliative dosing regimen for pain relief
depends on the affected tissue, and can include 8 Gy single dose, 4 Gy five times or 3 Gy 10 times 
[8]. Opioids are the most common drugs that are used in cancer related pain. They may also deviate 
dyspnea, cough and anxiety, which makes them useful in MPM symptom management. Local 
anesthetics, such as lidocaine, can be used in direct chest wall pain. Epidural or intrathecal treatments 
can be used in refractory cases [311]. Other possible drugs to alleviate symptoms are anti-convulsants,
corticosteroids, tricyclic antidepressants, and benzodiazepines [311].
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3. Aims and hypothesis
Previous publications have suggested that CT-based tumor volume assessment could provide accurate 
tumor burden evaluation with prognostic implications [5]. Moreover, unidimensional measurements 
of tumor thickness have been universally used for tumor response estimations [90]. Thus, we 
hypothesized that measuring tumor thickness with or without its circular and vertical pleural extent
in CT could reflect tumor size and its association with survival in our cohort. Secondly, activin A has 
been proven to be overexpressed in MPM tissue and cells in studies in our institution [10]. We 
hypothesized that circulating levels of activins could be elevated in MPM patients and that preclinical 
associations could be confirmed in a clinical setting. Thirdly, we hypothesized that cancer cachexia,
occurring frequently in other thoracic malignancies, is a prevalent condition also in MPM. In addition, 
weight loss, a hallmark of cachexia, is a common finding also in MPM [312]. Fourthly, since the
diagnosis of MPM can be difficult and the overall prognosis is dismal, we hypothesized that a 
proportion of patients with prolonged survival are wrongly diagnosed at baseline, and we re-evaluated 
these patients who formed a long-term survivor cohort.
The aims of this doctoral study were to evaluate clinical, radiological and histopathological factors 
that associate with the overall survival in MPM. The specific aims in studies I to IV were:
I) To define a simple and accurate method to approximately determine radiological tumor 
size and test its prognostic utility compared to other radiological characteristics (study I)
II) To prospectively analyze the role of circulating activins and follistatins in MPM (study II)
III) To evaluate the prevalence of cancer cachexia in MPM (study II)
IV) To confirm the diagnosis of MPM patients with extended survival, and search for 
histopathological (study III) and clinical (study IV) factors that predict prolonged survival.
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4. Materials and methods
4.1 Study population
All MPM patients diagnosed in Finland between 2002 to 2012 were identified from the FCR. These 
patients conformed the population base for studies I, III, and IV. Patients from the Helsinki University 
Hospital (HUS) region with available diagnostic CT scans formed the population of study I. From 
these patients, we selected the ones having epithelioid histology with survival less than five years to
establish a control group for studies III and IV. The epithelioid subtype was chosen as a control group
because of the assumption that the long-term survivals (LTS) would be of epithelioid subtype. After 
thorough histopathological and clinical confirmation of MPM diagnosis, all MPM patients with OS 
over five years were characterized as LTS in studies III and IV. The follow-up for study I closed on 
February 2017, for study III September 2018, and IV in January 2018.
For study II, we prospectively enrolled patients with a suspected thoracic malignancy from June 2016 
to January 2018 in the HUS area. The study was conducted as a pilot study for the newly established
Helsinki Biobank; hence recruited patients provided a written Biobank consent. We recruited patients 
before either diagnostic- or therapeutic surgery. This approach was decided upon to ensure that good 
quality tissue samples were available for firm MPM diagnosis. Patients with blood samples obtained 
postoperatively and an uncertain diagnosis or rare diagnosis were excluded from the study.
Figure 4 shows a detailed flowchart of the populations in studies I to IV. 
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Figure 4. Flowchart of patients in studies I to IV. MPM, malignant pleural mesothelioma; OS, overall survival; HUS, 
Helsinki University Hospital; CT, computed tomography; WDPM, well-differentiated papillary mesothelioma
1010 MPM patients 
diagnosed between          
2002 - 2012
OS over 60 months       
(n = 52)
Study III-IV = 43 
patients (long-term 
survivors)  
Excluded:
2 localized mesotheliomas
2 WDPMs
2 non-pleural sampes
1 miscoding
2 missing samples
HUS region patients     
(n = 439)
Study I = 161 patients
Study III-IV = 84 
patients (control group)
Excluded:
51 non-epithelioid 
8 non-pleural sample
15 uncertain diagnosis
3 missing samples
Excluded: 
278 patient without CT
149 prospectively 
collected patients between 
2016 - 2018
Excluded:  
25 postoperative sample
15 uncertain diagnosis
3 non-thoracic metastases
Study II = 106 patients
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4.2 Methods
4.2.1 Patient and disease information
Finnish Cancer Registry has maintained a nationwide cancer registry since 1953. FCR data are based 
on information collected from clinicians and pathologists [1]. For studies I, III, and IV the information 
from the FCR was complemented by mortality data from the National Registry of Causes of Death at 
Statistics Finland. In addition, individual clinical data used in all of these studies were collected from
hospital medical records. This clinical information was transferred and stored into a secure, certified 
electronic database maintained by Granitics Unify Med.
In addition to the basic patient characteristics, multiple categorizations and computational measures 
were used in these studies. Performance status was collected or estimated (if not readily available)
from the hospital medical records using WHO/Eastern Cooperative Oncology Group (ECOG) [313].
Comorbidities were measured using Charlson comorbidity index (CCI) score [314]. Smoking status 
was dichotomized into either never-smokers or former/current smokers with calculated pack-years.
Body mass index (BMI) was calculated by dividing weight by the square of height and expressed as 
kg/m2. Patients were defined as cachectic in study II, if they presented with over five percent weight 
loss over the past six months, if they had BMI below 20 kg/m2 with weight loss of over two percent, 
or CT-based skeletal muscle index (SMI) consistent with sarcopenia and weight loss of over two 
percent [167].
In these studies, a set of different approaches was used to obtain information about prior asbestos 
exposure. Decisions regarding worker’s compensation benefit were gathered from the National 
Workers’ Compensation Center Registry. Pleural plaques and calcifications are markers of prior 
asbestos exposure, and their presence were quantified from CT scans. Possible occupational asbestos 
exposure was documented from medical records. In addition, if available, pulmonary asbestos fiber 
counts were measured from autopsy lung samples using scanning transmission electron microscopy 
(STEM) at the Finnish Institute of Occupational Health.
4.2.2 Computed tomography assessment
Study I was based on CT characteristics. Also, for studies II and IV pretreatment CT scans were 
evaluated at the time of diagnosis. If available, contrast-enhancement chest and upper abdomen CT 
scans were preferred over other CT modalities. In all studies, CT images were measured blinded to 
the clinical information by a single radiologist. In study II, additional post-chemotherapy CT scans 
were evaluated to assess response to chemotherapy. The assessment of response was done by using 
both the mRECIST criteria (version 1.0) and the change of tumor size (TS) estimation [90].
The CT-based clinical staging was utilized using 8th edition of the AJCC/UICC TNM classification.
Because of the small number of patients in different stage groups, we combined stage groups IA, IB 
with II and IIIA with IIIB in study I, and IA with IB and IIIA with IIIB in study II, IV.
TS estimation was used in studies I, II, and IV. First, the maximal tumor thickness was evaluated in 
axial planes perpendicular to the chest wall or mediastinum. Second, to approximate the vertical and 
circular extension of the tumor, we divided the pleural cavity into three zones. For each of the three 
zones, the slice with the greatest circular extension of the tumor was evaluated separately. The final 
extension was summated at the level of the carina, and a four-tier scale was used: 0 = no tumor, 1 ≤ 
90º, 2 = 90-180º, 3≥180º (Figure 5) [315]. For example, if a small (less than 90º) tumor is located 
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only in the upper zone, the extension grade would be 1. If a similar tumor extension would be found 
also in the middle and lower zone, the grade would be 2 or 3 depending on the final summation. 
Finally, the TS was estimated by multiplying the extent grade with the maximal tumor thickness.
Figure 5. The tumor extension grading scale in the pleural cavity [315].
In study I, pleural effusion was measured using its maximal axial thickness. Fibrosis and emphysema 
scores were evaluated on a previously published scale, where 0 represents normal findings and 5 
extreme changes [316,317]. A set of 30 (19%) images were randomly re-evaluated after a month by
the same radiologist to determine the intra-rater agreement. 
For study II, individual SMI used in cachexia assessment was evaluated from pretreatment CT images 
according to a previously published method [318]. The cross-sectional areas of the psoas, quadratus 
lumborum, paraspinal, transverse abdominal, external oblique, internal oblique, and rectus abdominis 
muscles were identified at the level of vertebra L3. These muscle areas were quantified using Osirix© 
version 33 (32-bit Pixmeo, Sarl, Switzerland). SMI was calculated correcting the skeletal muscle area
for height (m2). The cut-off used for defining sarcopenia was based on previous consensus report: 
SMI below 55 cm2/m2 for men and 39 cm2/m2 for female [167].
4.2.3 Activin assays and other laboratory measurements
For study II, pre-treatment serum samples were prospectively collected from participating patients. 
The serum was stored in the Helsinki Biobank after centrifugation at -80˚C. Serum activin A, activin 
B, FS, and FSTL3 levels were measured by ELISA from AnshLabs LLC, Webster, USA. A BioRad 
Benchmark microplate reader was used for activins measurements and Hidex Sense for FS and 
FSTL3 measurements. The absorbance was measured at 450 nm to quantify biomarker levels. In 
addition, CRP levels (cutoff of 3 mg/L) and hemoglobin were measured at the time of the biomarker 
collection as part of the routine preoperative workup and included in the study.
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4.2.4 Histopathological evaluation
Studies III and IV were based on histopathological confirmation of patients with a survival of over 
five years. First, the initial diagnoses were confirmed, along with control group, by evaluating tumor 
samples blindly to the survival data. Information on clinical and radiological characteristics was 
added to the histopathological evaluation, if needed. In general, the first diagnostic sample was 
evaluated but more representative samples were used instead, if it was obtained within three months.
If the sample included several tissue blocks, all of these were studied but only one slide was selected 
for further analyses. The diagnosis was based on the current standards of morphological and IHC 
criteria [17]. Additional IHC stains were carried out if at least two positive and two negative 
mesothelial markers were not available on the diagnostic samples. In addition, if enough tumor tissue 
was available, we constructed formalin-fixed paraffin embedded tissue microarray (TMA) blocks, on
which BAP1 IHC-staining was performed. Figure 2 shows the distribution of excluded patients in 
these studies. 
After the initial diagnosis was confirmed, a second evaluation round was performed blindly to the 
clinical information in study III. During the evaluation, all samples were classified according to their
size into either large, small, or scant, independently of the biopsy method used to obtain the sample.
The three-tier nuclear grade was established using a previously published method by adding nuclear 
atypia and mitotic count [245]. Nuclear size and irregularity were assessed at x 400 magnification, 
and scored into either mild, moderate or severe atypia. The mitotic count was calculated from the 
spots with highest mitotic activity using 50 high power field (HPF) and determined the average per 
10 HPF. After that, tumors were divided into three-point mitotic score. The final nuclear grade was 
calculated by adding mitotic score to nuclear atypia scale. In addition to nuclear grade, morphological 
subtypes were recorded as five percent increments, and classified by predominant growth pattern:
trabecular, tubulopapillary, solid, micropapillary, or pleomorphic. For survival analyses, these 
subgroups were classified into low-grade (trabecular, tubulopapillary) or high-grade (solid, 
micropapillary, pleomorphic) according to previous publications [185]. We also reported the presence 
of necrosis, myxoid stroma (positive if it contains over 50% of the tumor volume). In addition to 
these previously published features, we noted tumor density (the percentage of tumor in the sample
evaluated in 10x field), presence of tubular structures covered with a single layer of mesothelial cells 
(single layer), and the presence of exophytic growth (large stout fibrovascular papillae - “polypoid-
pattern”).
4.3 Ethical considerations
All studies were conducted in accordance with the Declaration of Helsinki. Studies I, III, and IV were 
retrospective observational studies, which includes information from several nationwide registries.
Permissions to use these data and tissue samples were received from HUS (HUS/746/2018), Finnish 
National Institute for Health and Welfare, National Workers Compensation Center and Statistics 
Finland. Valvira, a national supervisor of the social and health care, has granted permission to study 
tissue samples (752/06.01.03.01/2016). A statement of approval for the study protocol was given by 
the Ethical Committee of HUS (418/13/03/02/2015).
Study II was a prospective observational study, that was conducted as a pilot study for Helsinki 
Biobank. All recruited patients provided a written Biobank consent. Research permission was granted 
by the Institutional Review Board of HUS (HUS/152/2016), Scientific Steering Committee of the 
Helsinki Biobank (HUS/359/2017), and the Ethical Committee of HUS (HUS/1057/2019).
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4.4 Statistical methods
In all studies, categorical variables are presented as number of patients with percentages, and 
continuous values as medians with range or interquartile range (IQR) or mean with standard deviation 
(SD). All reported p-values are based on two-tailed tests. Bonferroni correction for multiple tests was 
used in studies II and III, if multiple comparisons were made. The chi-square test was used for testing 
between categorical variables and Mann-Whitney’s U-test or Kruskal-Wallis test for continuous 
variables. The nonparametric Spearman correlation coefficient was used to assess the relationships 
between two continuous variables. Intra-observer agreement was defined using weighted kappa (wκ) 
for categorical variables and intra-class correlation (ICC) for continuous variables in study I.
The survival analyses were carried from the date of diagnosis to the end of follow-up or until death. 
Both cancer-specific and all-cause mortality were used in the analyses. Since the vast majority of 
patients died of MPM, no significant differences were noted between these mortality types. Survival 
curves were computed using the Kaplan-Meier method, and the statistical significance was 
determined using the log rank test. The Cox’s proportional hazards regression model was used to 
estimate the strength of the association between various factors and survival. 
In study I, the predictors for survival were first identified by univariate analyses. The significant
predictors found were then included into a multivariate model consisting of CT-based TS evaluation,
laterality, pleural effusion, TNM stage, pleural calcification, along with histological subtype, sex, and 
age. Histopathological factors that had shown association with survival before or identified in 
univariate analyses (nuclear grade, histologic subtypes, necrosis, exophytic polypoid growth, single 
layer, and tumor density) were entered into a multivariate model in study III. Similarly, the final 
multivariate model in study IV consisted TS, clinical TNM stage, occupational disease, and ECOG 
PS. In addition, both models were adjusted with age, sex, and treatment status. Study II focused on 
associations between clinical endpoints and circulating biomarker levels. The logistic or linear 
regression analysis was used to determine the independent effect of activin A on cachexia or 
chemotherapy response, using adjustments for age, sex, CRP, and TS.
Statistical analyses in Study I were performed using SAS System for Windows version 9.4 (SAS 
institute, Inc. Cary, NC) or SPSS version 24.0 (IBM SPSS Statistics, Chigaco, IL), and in study II-
IV using SPSS version 25.0. In all studies, a p-value less than 0.05 was considered significant.
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5. Results
5.1 Patient baseline characteristics 
Table 5 presents the characteristics and distributions of MPM patients included in our studies. In 
summary, we found that most of MPM patients were old men with previous asbestos exposure. Apart 
from the LTS group, the median survival was scarce, and most patients died due to MPM. In study 
II, biomarker levels were compared to NSCLC and benign lung tumor patients. The distributions of 
baseline information between main study groups can be viewed in the study II attached at the end of 
the thesis.
Table 5. Malignant pleural mesothelioma patient demographics in studies I to IV
* data missing from 4 patients; 1. LTS, long-term survivals; 2. NA, not available; 3. CCI, Charles comorbidity 
index; 4. SD, standard deviation; 5. ECOG PS, eastern cooperative oncology group; 6. refers to clinical stage; 7.
IQR, interquartile range; 8. OS, overall survival; 9, MPM, malignant mesothelioma
Characteristics Study I Study II                               Study III-IV
LTS1 Control
Patients 161 21 43 84
Age, years, (median, range) 69 (43-89) 71 (63-77) 61 (27-87) 67 (54-84)
Sex, male, n (%) 138 (86) 20 (95) 30 (70) 74 (88)
Asbestos exposure, yes, n (%) 109 (68) NA2 18 (42) 63 (75)
CCI3, mean (SD)4 NA 0.8 ± 1.2 0.60 ± 0.8 0.67 ± 0.9
ECOG PS5, n (%)
   0
   > 1
NA 13 (62)
8   (38)
39 (91)
4   (9)
33 (39)
51 (61)
Histology, n (%)
   Epithelioid 
   Biphasic
   Sarcomatoid
111 (69)
23   (14)
27   (17)
14 (67)
3   (14)
4  (19)
45 (100) 84 (100)
Stage6, n (%)
   No visible tumor
   Stage I
   Stage II
   Stage III
   Stage IV
12 (7)
46 (29)
5   (3)
74 (46)
24 (15)
3 (14)
2 (10)
14 (66)
2 (10)
*
7  (18)
16 (41)
3 (8)
11 (28)
2 (5)
4   (5)
27 (32)
3   (4)
37 (44)
13 (15)
Tumor size, mm, median (IQR)7 36.0 (12.0-78.0) 45.0 (2.90-61.5) 17.0 (2.3-45.3) 30.0 (10-62.3)
OS8, median (IQR) 9.1 (3.3-19.7) 7.6 (4.5-11.8) 79.3 (69.3-99.3) 11.3 (5.6-19.2)
Cause of death, n (%)
   MPM9
   Other cause
   Alive
153 (95)
2     (1)
6     (4)
8  (38)
1  (5)
12 (57)
32 (74)
3   (7)
8   (19)
83 (99)
1   (1)
0
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5.2 Computed tomography and mortality (study I)
There were 161 MPM patients at HUS district with diagnostic CT-images available. An overview of 
the most common CT characteristics is found in Table 6. The most common CT finding was unilateral 
pleural thickening with pleural effusion. Some form of emphysema was noted in 50 (31%) and 
fibrosis in 41 (26%) of patients. Most patients had a stage III disease, while 12 (7%) patients had no 
recognizable tumor in the CT scan (Table 5).
The estimation of TS associated with different MPM histological subgroups. Largest size was noted 
in sarcomatoid subtype (median 66.0, p = 0.003). The TS increased along with advanced tumor stage 
(p < 0.001), as well as correlated with TNM T-class (r = 0.70, p <0.001) and N-class (r = 0.41, p < 
0.001). The intra-observer agreement for TS estimation was excellent (ICC 0.93, 95% CI 0.86-0.96).
Other measurements can be found in the original publication (study I) at the end of this thesis.
The median survival-time was 9.1 (range 0-104) months. Univariate survival analyses showed that
age (p = 0.061), laterality (p = 0.067), TS (p < 0.001), the amount of pleural effusion (p = 0.038), the 
presence of bilateral pleural calcification (p = 0.046), stage (p = 0.07), and histological subtype (p < 
0.001) were associated with mortality. In multivariate analyses, high TS (HR 1.01, 95% CI 1.01-1.02,
p < 0.001) and amount of pleural effusion (HR 1.01, 95% CI 1.01-1.02, p < 0.001) along with 
sarcomatoid histology (HR 4.71, 95% CI 2.88-7.69, p < 0.001) were independent predictors of poor 
survival. When TS was divided into its initial factors, both tumor thickness, and pleural extent grade 
predicted survival in univariate analyses, but only extent grade was significant (p = 0.001) after 
adjustments. The Kaplan-Meier survival plot is shown in Figure 6, when TS was dichotomized by its
median.
Table 6. Overview of radiological characteristics (n = 161)
CT finding Value
Pleural thickening, n (%)
Pleural effusion, n (%)
Pleural effusion (mm); median (range)
149 (93)
144 (89)
50.0 (0-165)
Tumor thickness (mm); median (range)
Tumor extent grade; n (%)
   Grade 0
   Grade 1
   Grade 2 
   Grade 3
Tumor size (mm); median (range)
Pleural plaques, n (%)
Pleural calcification, n (%)
18.0 (0-102)
12 (7)
53 (33)
32 (20)
64 (40)
36 (0-306)
115 (71)
98   (61)
49 
 
_______________________________________________________________________________________________          
Figure 6. Kaplan-Meier curve showing survival according to tumor size. TS, tumor size, mm; mOS, median 
overall survival
5.3 Circulating activins and follistatins in MPM (study II)
A total of 106 patients were recruited in study II. The main study groups consisted of 21 (21%) MPM, 
59 (58%) NSCLC, and 22 (21%) patients with benign lung tumors. Table 7 summarizes the values of 
different circulative biomarker levels in these groups. All biomarker levels were the highest in MPM.
Follistatin and FSTL3 levels showed significant differences across the treatment groups, whereas
circulating activin A was the best to discriminate between these groups. None of the biomarkers 
differentiated between histological subtypes of MPM or NSCLC.
Table 7. Circulating biomarker levels in the main study groups. The P-values indicates the differences
between these groups.
1. MPM, malignant pleural mesothelioma; 2. NSCLC, non-small cell lung cancer; 3. IQR, interquartile range
MPM1 (n=21) NSCLC2 (n = 59) Benign tumor (n=22) P-value
Activin A, median (IQR)3, ng/ml 1.21 (0.90-2.02) 0.68 (0.49-0.85) 0.40 (0.32-0.54) <0.001
Activin B, median (IQR), ng/ml 0.12 (0.10-0.18) 0.10 (0.09-0.13) 0.10 (0.08-0.12) 0.121
Follistatin, median (IQR), ng/ml 3.50 (2.48-3.98) 2.51 (1.93-3.06) 2.34 (1.77-2.99) 0.013
FSTL3, median (IQR), ng/ml 14.75 (11.13-35.13) 11.25 (10.00-14.50) 9.13 (7.31-10.06) <0.001
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Twelve (57%) MPM patients were cachectic compared to seven (12%) NSCLC patients at diagnosis
(p < 0.001). Figure 7 shows different biomarker levels according to cachexia: activin A was the only 
marker that was statistically higher in patients with cachexia (p = 0.001). Circulating activin A levels 
correlated also with age (r = 0.414; p < 0.01), and CRP (r = 0.468; p < 0.01). The association with 
cachexia and activin A remained significant after adjustments for age, sex, CRP (p = 0.047).
In MPM patients, activin A was the only biomarker that was positively correlated with pretreatment 
CT-based TS assessment (r = 0.549; p = 0.010) but did not associate with TNM stage (p = 0.542). 
Twelve (57%) MPM patients received first-line platinum-based chemotherapy. When comparing TS 
change between pre- and post-chemotherapy, we found that patients with progressive disease had 
almost three-fold higher circulating activin A levels compared to patients with partial response or 
stable disease (median 3.09 versus 1.21 ng/ml; p = 0.0028). This association remained significant 
after adjustments for TS, CRP, sex, and age (p = 0.008). The findings were similar when assessing 
the chemotherapy response with mRECIST criteria, and mRECIST correlated positively with TS 
change (r = 0.918, p < 0.001).
Figure 7. Median levels of activins and follistatins in patients with cancer cachexia. Activin A levels were 
higher in cachectic patients (*** indicates significant p-value).
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5.4 Clinical and histopathological factors and long-term survival 
(study III-IV)
Figure 2 summarizes the diagnostic validation process for both LTS and control group. A total of 127
tumor specimens were analyzed: 43 (34%) were LTS and 84 (66%) formed the control group. A 
median of three (IQR 1-5) H&E slides were reviewed from each tumor. The diagnostic accuracy of 
the original MPM diagnosis was good as only one (0.5%) NSCLC patient was miscoded at the cancer 
registry as MPM. In addition, we identified two LMMs (0.9%) and two WDMPs (0.9%) that were 
originally diagnosed as diffuse MPM. BAP1 IHC was available in 57 (45%) patients and was negative 
in 12/14 (86%) LTS patients and 25/43 (58%) control patients (p = 0.150).
Clinical characteristics can be viewed in Table 5. Compared with the control group, the LTS were 
younger, more frequently females, and their performance status was better at the time of diagnosis. 
The proportion of prior malignancies was similar in both study groups (p = 0.213). LTS patients were 
more likely to undergo surgery with a p-value trending towards significance (44% versus 27%; p = 
0.057). LTS patients were more likely to be treated with chemotherapy (p = 0.048) or RT (p = 0.014).
The main histopathological differences between the study groups are summarized in Table 8. In 
summary, LTS tumors had mostly tubulopapillary growth pattern with nuclear grade I, whereas solid 
growth pattern and grade II were more common in controls (p < 0.001). All but one tumor had 
exophytic polypoid growth pattern in LTS tumors (p < 0.001). In contrast, one LTS tumor had 
necrosis compared to sixteen in control group (p <0.007).
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1. LTS, long-term survival over five years; 2. Histologic subtypes combined for survival analyses: high-grade 
(solid, micropapillary), low-grade (trabecular, tubulopapillary)
In study IV, we observed that LTS patients had lower asbestos exposure than control group when 
measured either by self-reported (44% versus 76%; p < 0.001) or occupational compensations (42% 
versus 75%; p < 0.001) as well as lower fiber count concentrations in the lung tissue (median 0.4 
mf/g, IQR 0.2-5.4 versus 9.0, IQR 0.6-132.5; p = 0.019). In study III, we investigated the association 
between the fiber count and histopathological parameters. We found that the total concentration of 
lung fibers associated with nuclear grade, so that the lowest concentrations were found on grade I 
(median 0.60, IQR 0.20-8.60 mf/g) and the highest in grade III (median 280.0, IQR 150-280 mf/g) (p 
< 0.001). Likewise, higher tissue fiber content was more likely to be found in tumors with necrosis 
than in tumors without necrosis (p = 0.027).
Survival times and cause of death can be seen in Table 5. In study III, univariate survival analyses 
showed that the histopathological findings that affected survival were nuclear grade (p < 0.001), 
epithelioid histologic subtypes (p < 0.001), necrosis (p = 0.002), tumor density (p < 0.001) and the 
presence of exophytic polypoid growth (p = 0.002) or single layer (p <0.001). Similarly, age (p = 
0.002), TS (p = 0.002), ECOG PS (p < 0.001), and occupational asbestos disease (p = 0.008)
Table 8. Main histopathological findings according to study groups
LTS¹ Control p-value
Sample size, n (%)
   Large
Small
   Scant
Nuclear grade, n (%)
   Grade I
   Grade II
   Grade III
33 (77)
7   (16)
3   (7)
34 (90)
4   (10)
0
52 (62)
28 (33)
4   (5)
28 (34)
49 (61)
4   (5)
0.123
<0.001
Histologic subtypes, n (%)
Trabecular
Tubulopapillary
Solid
Micropapillary
2   (5)
30 (70)
9   (20)
2   (5)
0
24 (29)
59 (70)
1   (1)
<0.001
Compound histologic subtype2, n (%)
   High-grade
   Low-grade
11 (25)
32 (75)
60 (71)
24 (29)
<0.001
Myxoid stroma, n (%)
   Absent
   Present
40 (93)
3   (7)
80 (95)
4   (5)
0.605
Necrosis, n (%)
   Absent
   Present
42 (98)
1   (2)
68 (81)
16 (19)
0.007
Exophytic polypoid growth pattern, n (%)
   Absent
   Present
32 (74)
11 (26)
83 (99)
1   (1)
<0.001
Single layer, n (%)
   Absent
   Present
16 (37)
27 (63)
61 (73)
23 (27)
<0.001
Tumor density, %, median (IQR)   50.0 (30 – 60) 70.0 (45 – 81) <0.001
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associated with survival in study IV. These variables were entered into two separate multivariate 
models along with age, sex, and treatment status. The final multivariate models are presented in Table 
9. In summary, nuclear grade, ECOG performance status, TS, and the presence of exophytic polypoid 
growth were independent predictors of survival. When treatment was added to the multivariate model
B it showed that both surgery (HR 0.38, 95% CI 0.21-0.69) and chemotherapy (HR 0.48, 95% CI 
0.28-0.81) were independent predictors for better survival when compared to patients with best 
supportive care.
Histopathological (A) cox proportional hazard model was adjusted for age, sex, nuclear grade, histologic subtypes, 
necrosis, exophytic polypoid growth, single layer, tumor density, and treatment; Clinical (B) model adjusted for 
age, sex, ECOG performance status, TS, clinical TNM stage, occupational disease, and treatment; 1. HR, hazard 
ratio; 2. CI, confidence interval; 3. ECOG, eastern cooperative oncology groups; 4. TS, tumor size, mm.
Table 9. Multivariate analysis associated with overall survival
Study IIIA Study IVB
Variable HR¹ (95% CI²) p-value HR (95% CI) p-value
Age (continuous)
Sex, male
Nuclear grade
   Grade I
   Grade II
   Grade III
1.01   (0.99 – 1.03)
1.25   (0.71 – 2.18)
1.00
4.43   (2.51– 7.82)
16.39 (4.57 – 58.76)
0.674
0.440
<0.001
1.02 (0.99 – 1.04)
1.06 (0.57 – 1.96)
0.179
0.861
Histologic subtypes, low-grade 0.71   (0.39 – 1.26) 0.241
Necrosis, yes 1.26   (0.66 – 2.42) 0.484
Exophytic polypoid growth, yes 0.43   (0.21 – 0.89) 0.024
Single layer, yes 0.76   (0.46 – 1.26) 0.288
Tumor density (continuous)
EGOC3 performance status
   PS 0
   PS I-III
TS (continuous)
Clinical stage
   No measurable disease
   Stage I
   Stage II
   Stage III
   Stage IV
Occupational disease, yes
1.00   (0.99 – 1.01) 0.883
1.00
2.97 (1.82 – 4.82)
1.01 (1.00 – 1.01)
1.00
1.16 (0.55 – 2.45)
1.76 (0.56 – 5.57)
1.27 (0.57 – 2.81)
1.27 (0.48 – 3.36)
1.29 (0.78 – 2.16)
<0.001
0.022
0.903
0.694
0.334
0.562
0.631
0.314
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6. Discussion
This doctoral thesis studied clinical, radiological, and histological factors in MPM and their relation 
to survival as well as other important clinical endpoints. In summary, we could confirm several 
previously published prognostic factors as well as observed novel features that may be helpful in 
predicting survival. The independent radiological prognostic factors found in study I were TS and the 
amount of pleural effusion among with the histological subgroups. Similarly, when studying only 
patients with epithelioid subtype in study III-IV TS and ECOG performance status as well as 
histopathological nuclear grade and the presence of exophytic polypoid growth were the strongest 
predictors of survival. In addition, we confirmed that circulating activin A is elevated in MPM and is 
associated with cancer cachexia, TS, and chemotherapy response.
 
6.1 Patient related prognostic factors 
Age, sex, comorbidities and performance status are examples of host-related prognostic factors [207].
Several studies have found their significance in numerous malignancies, including MPM [20,23,221].
The male predominance, observed in our studies is mostly explained by the occupational nature of 
the disease [35]. Several studies have also observed that male sex is an adverse prognostic factor 
[23,211]. In study IV, we found that LTS patients were younger and more commonly female than 
controls, but neither of them affected survival after adjustments. When comparing the baseline 
characteristics against NSCLC patients in study II, we observed that MPM patients had less smoking 
history and comorbidities than lung cancer patients. This is not surprising, since smoking is the main 
etiological factor in lung cancer and also contributes to several other diseases, while no clear
associations have been reported between smoking and MPM [2,319].
Contrary to previous results, we did not find any survival associations with comorbidities, when
assessed by the Charlson comorbidity scale [221]. Performance status, as evaluated by ECOG scale 
or other quantitative measurements, is an important and universal measurement in cancer patients
[320]. It does not only play a role in prognostic assessment, but also guides treatment options in 
individual patients. Patients with worse PS tend not to tolerate most of the treatments and are not
usually included in the clinical trials. Hence, in general, the prognostic utility of PS cannot be studied 
in clinical trials, while large population-based studies typically lack this information [211].
Unsurprisingly, in study IV we found that most of LTS patients were PS scale 0 and that PS was also 
an independent prognostic factor after adjustments. This is in line with previous studies on MPM as 
well as other cancers [20,320]. The weakness of this evaluation is that it was determined at baseline, 
and it can substantially change in MPM patients after certain treatments such as thoracentesis. In 
addition, it is a subjective measurement and had to be estimated afterwards for some patients due to 
missing information in the medical records.
The role of asbestos as an etiological factor of MPM is firmly established, but its prognostic 
significance has been debated [211,321]. Some studies have reported a worse outcome in patients 
with a prior asbestos exposure [222], while others have found no survival associations [211].
Establishing accurate anamnesis for asbestos exposure can be complicated due to a long latency 
period between asbestos exposure and the MPM development. Moreover, histories and the amount
of exposure are generally reliable at a cohort level, but their reliability decreases at the individual 
level [57]. Non- or para-occupational exposure is even harder to quantify. To overcome these
limitations, specific questionnaires and calculations have been developed to capture exposure more 
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reliably, but these can only be reliably used in a prospective design. Due to these limitations, we
measured the role of asbestos in multiple different ways. In study IV, they all showed similar results:
LTS patients were less likely to have occupational asbestos disease, they had fewer pleural plaques 
in CT, and lower asbestos fiber burden in TEM analyses when compared to control group. However, 
occupational asbestos disease was a significant predictor of survival only in univariate analyses but 
not after adjustments. Also, the number of total fiber analyses made in LTS patients (31%) was low, 
which prevented us from reliably studying its prognostic significance or the associations to asbestos 
fiber types.
In study IV we studied the role of therapy. In line with previous retrospective studies, we found that 
patients undergoing surgery or chemotherapy were associated with longer survival compared to
patients with no therapy [19,222]. This is not surprising, since usually only suitable patients are 
selected for certain therapies and not all of the confounders can be adjusted for. Furthermore, due to 
the long study period, differences in treatment over time and across regions could have affected these 
results. Nevertheless, the association between treatment and prognosis remained significant after 
adjustments for PS status, TNM stage, age, sex, TS, and occupational disease. None of the patients 
received multimodality treatment, but different lines of treatments were given when the cancer 
progressed. Interestingly, a subset of LTS patients (9%) did not receive any kind of therapy, primarily 
due to their own choice. The fact that some patients had prolonged survival in the absence of any
therapy underlies the heterogeneity and indolent behavior of some of the tumors. Thus, prospective, 
preferably randomized, studies are needed to fully study the role of therapies in this heterogenous 
disease.
6.2 Computed tomography assessment and survival
Because of its wide availability and limited cost, CT is the primary imaging modality to assess the 
extension of MPM and the follow-up after treatment. In study I, we evaluated MPM patients’ CT 
characteristics at the time of diagnosis. In line with previous studies, we found that the most common 
CT findings were pleural thickening among with pleural effusion and pleural plaques or calcification
[41]. In accordance with previous findings, most patients were diagnosed at a late stage [106].
Mesothelioma evaluation by CT is challenging due to its’ unique morphology, which is characterized 
by uniform or separate lesions that extend from the pleural surface to the surrounding tissues with 
variable thickness. This leads to the well-known limitations regarding tumor burden assessment and 
staging using current imaging modalities. TNM stage T-category refers to the invasion into adjacent 
structures rather than the actual tumor size. Moreover, assessing T-category from CT-images is 
subjective and CT tends to underestimate the true tumor extent, which leads to discrepancies when 
compared to pathological stage [107]. Also, many kinds of incidental findings (such as lung nodules, 
atelectasis, and adrenal incidentalomas) are relative common in CT. These incidental findings cannot 
easily be classified as metastases (M1) or benign findings (M0) by CT alone. Thus, current guidelines 
suggest using multiple imaging modalities and possible invasive biopsies in the staging process [8,9].
Limitations in the CT assessment and relatively small sample sizes may explain why TNM stage did 
not show prognostic utility after adjustments in our study. Indeed, a larger study consisting of 2141 
MPM patients from IASLC database found that both pathological stage and clinical stage were
independent prognostic factors in different multivariate models [106]. However, they also reported 
discrepancies between pathological and clinical staging, which have launched a search for other 
quantitative methods in order to improve clinical staging.
Multiple approaches, such as tumor volumetry or tumor thickness measurements have been proposed 
to replace or add to the T-category of the TNM stage [5,6]. From these, tumor volumetry is a more 
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comprehensive and better validated method than measuring tumor thickness. In addition, one study 
combined tumor volumetry and maximal tumor thickness in the interlobar fissures and found that this 
combination outperformed clinical TNM staging in prognostic evaluation [322]. However, 
quantifying exact tumor volume from CT images can be complicated, time-consuming, and several 
different image softwares have been used in previous studies [89]. In addition, distinguishing 
mesothelioma from the adjacent structures on CT can be a subjective process and prone to errors even 
if computer assistance is used [91]. In study I, we proposed a novel and practical tumor burden (TS) 
estimation, which accounts for maximal tumor thickness as well as tumor pleural extension. This idea 
arose from a previously published method used for evaluating pleural abnormalities such as pleural 
plaques [323]. After our publication, a study evaluated the prognostic value of tumor volumetry, TNM 
stage, and number of macroscopic tumor sites (i.e. pleural extent), and found that they all predicted 
survival by similar effect and that the combination of tumor volume and pleural extent was the most
powerful prognostic factor [239]. The advantages of our method are that it is practical and easy to 
measure and has excellent intra-observer agreement. The disadvantage is that it is only a crude 
estimate of the actual size. Despite this, we observed an association with sarcomatoid histology and 
TNM T- and N-classes. In survival analyses, it was an independent predictor for survival in study I
as well as in another cohort in study IV.
Other CT-characteristics that associated with survival in study I were the thickness of pleural effusion, 
tumor laterality, and the presence of pleural calcification. From these, the amount of pleural effusion 
remained significant after adjustments. Even if previous studies have found similar associations, the
reasons for this remains unclear [41]. We hypothesize that the presence of effusion might reflect the 
biological activity of the disease. However, measuring the thickness is a crude estimation of the real 
amount of effusion and prone to errors such as previous thoracentesis. 
The current standard for MPM response evaluation is mesothelioma-specific mRECIST criteria, 
which combines six perpendicular unidimensional tumor thickness measurements from three separate 
sections of the pleural tumor [90]. This criterion has been criticized for its high interobserver 
variability and imprecision in measurements. Thus, a revision was made in 2018 with several 
refinements and clarifications on the methodology [91].  Also, alternative approaches such as 
measuring changes in linear tumor thickness or tumor volume have been used as a marker for 
treatment response [324–326]. In study II, we used TS change for treatment response evaluation and 
found a very strong correlation when compared to the original mRECIST criteria.
6.3 Circulating activins and follistatins in MPM
In study II, we investigated the levels of circulating activin A and B as well as their endogenous 
antagonists` follistatin and FSTL3 in patients with thoracic malignancy. We observed that particularly 
levels of activin A were elevated in MPM patients compared to NSCLC and benign lung lesions.
Similar findings have been found in previous preclinical studies and in one clinical study [10,12]. In 
the latter, Hoda et al reported activin A levels to be an independent prognostic factor in MPM patients 
associated with histological subtypes and CT-based tumor volume. Our sample size was not large 
enough for a prognostic evaluation and we did not find any differences between the histological 
groups. However, we observed several clinically meaningful associations, which could be seen as a 
surrogate for survival.
An international expert panel defined cancer cachexia as a multifactorial syndrome with ongoing loss 
of skeletal muscle mass, with or without loss of fat mass, that cannot be reversed by nutritional 
support and leads to progressive functional impairment [167]. It is associated with various 
physiological and metabolic changes, such as systemic inflammation, leading to reduced tolerance to 
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cancer therapies and poor outcome. Indeed, it is considered to be responsible for up to 20% of all 
cancer deaths [167]. Previous studies have reported widely varying estimates for the prevalence of 
cancer cachexia in other thoracic cancers such as NSCLC, while little data is available in MPM 
patients [312]. We observed that over half of MPM patients were defined as cachectic at diagnosis.
This is not surprising, since the presence of weight loss, a hallmark in cachexia, is a common 
condition in MPM with negative prognostic impact [212]. In comparison to MPM, we found that only
12% NSCLC patients were cachectic at diagnosis. This difference might be explained by the different 
disease stages in MPM and lung cancer patients. 
Out of these biomarkers, activin A had the most clinical value. In line with previous preclinical studies 
and clinical studies in colorectal and lung cancer patients, activin A was the only marker associated 
with cancer cachexia [13,14]. The association remained significant after adjustments on inflammation 
marker CRP, age, and sex. The link between cachexia and systemic inflammation has been firmly 
established, even though the exact mechanisms are unclear. Interestingly, the results of anti-
inflammatory medication have been variable in reversing cachexia, whereas inhibition of activin 
receptor signaling or blocking activin via soluble follistatin have withdrawn cachexia changes in 
animal as well as clinical studies without affecting inflammatory markers [14,172,178].
In addition to the relation between activin A and cancer cachexia, we observed that activin A levels 
were positively correlated with pretreatment TS. This is in line with previous work, where a similar 
correlation was observed between activin A and tumor volumetry [12]. In the exploratory analysis,
they also observed that patients who had a dramatic decrease in plasma activin A levels after 
chemotherapy experienced also a major therapeutic response. We also looked at chemotherapy 
response after a report where activin A was identified as a potential mediator for platinum-based 
chemotherapy resistance [15]. In that study, it was observed that blocking activin signaling overcame
chemoresistance as well as prevented cisplatin-induced nephrotoxity in lung adenocarcinoma models.
Our exploratory findings are comparable to these associations, since the patients with progressive 
disease after chemotherapy had almost three times higher activin A levels compared to patients with 
partial response or stable disease. This finding remained significant after adjustments, but it needs to 
be validated in larger cohorts.
6.4 Histopathological factors and overall survival
Histological subtypes are one of the strongest prognostic factors in MPM. Epithelioid is the most 
frequent histopathological subtype with the best prognosis [25]. In study III, we analyzed the 
histopathological features predictive of prolonged survival in patients within the epithelioid subgroup. 
We used previously published characters and sought to identify novel prognostic features.
Before analyzing prognostic features, we made a thorough assessment of the original MPM diagnosis. 
These steps included a clinical, radiological and histopathological evaluation in order to confirm the
initial diagnosis. We performed additional IHC stains, including BAP1, which is considered to be 
helpful in distinguishing benign mesothelial proliferation from malignant [17]. However, the loss of 
BAP1 is observed approximately in 60% of epithelioid mesotheliomas and it is also a common finding 
in other malignancies [327]. To our surprise, more LTS tumors where BAP1 negative than controls, 
although the difference was not significant. Since patients with germline BAP1 mutations have better 
prognosis and exhibit similar clinical features than we observed in our LTS group (low asbestos 
burden, young age, more female), it is possible that some of the LTS patients have an inherited BAP1
germline mutation [83,328]. However, other common features in hereditary cancer syndromes, such 
as a family history of cancer, other BAP1-related cancers, or prior mesotheliomas in the family were 
58 
 
absent in most of the cases. Indeed, some authors have proposed that if some of these features are 
present, genetic testing for BAP1 should be considered, leading to possible mesothelioma screening 
or routine monitoring within the family [328]. Unfortunately, the germline mutations from this cohort 
could not be assessed due to the lack of adequate samples.
In our cohort, the proportion of patients exceeding five-year survival is equivalent to previous
population based studies (approximately 5%) [211]. In contrast to our original hypothesis, we found 
that the accuracy of the original diagnosis was good in the LTS cohort. Only one malignancy was 
found to be a non-mesothelioma, which was the result of miscoding at the cancer registry. We could 
also confirm two LMMs and two WDPMs that were originally diagnosed as diffuse MPM. One 
explanation for the good diagnostic accuracy is that some of the cases were originally evaluated in 
the nationwide mesothelioma expert panel. In addition, at least in the university hospitals, all of the 
new mesothelioma cases are evaluated in a multidisciplinary team in order to solve diagnostic and 
treatment issues. However, it could be concluded that the main reason for diagnostic accuracy appears 
to be the familiarity for this diagnosis among the pathologists.
LMMs are histologically indistinguishable from MPM but don’t share similar diffuse pleural spread.
Compared to MPM, LMMs can be potentially extirpated with R0 resection, leading to favorable 
prognosis [17,203]. Thus, even though the differential diagnosis can be challenging, it is crucial to 
separate diffuse MPM from its localized counterpart. As discussed by Allen et al., sometimes early 
presentation of MPM as a single dominant mass can mimic LMMs, whereupon only careful
observation can distinguish these diagnoses [202].
The differential diagnosis of WDPM and diffuse MPM is challenging and somewhat unsettled.
Histological distinction is based on cytological and/or architectural atypia with stromal invasion: true 
WDPMs have usually no, or only limited, invasion in contrast to MPM, where tumor invasion is a 
central part of the diagnosis [17]. Recently, BAP1 negativity has been suggested to be incompatible 
with WDPM [108]. In addition to two WDPMs with no invasion, the diagnosis of WDPM with
minimal invasive foci could be considered in  three of our cases [205]. However, these cases showed 
clinical behavior compatible with MPM (BAP1 loss when available, MPM as a cause of death, 
metastasis, or additional biopsy with profound invasion), and thus were included in the study as 
diffuse MPMs. WDPMs are rare variants of mesothelioma, which are typically found in the
peritoneum in young women [329]. It is defined as a tumor with papillary architecture and bland 
cytology with superficial spread [17]. WDPMs typically have an indolent clinical behavior, especially 
if located in the peritoneum, while some have reported that pleural WDPMs can progress to diffuse 
MPMs [330]. We identified a WDPM-like polypoid pattern in part of the MPM patients, called an 
exophytic polypoid growth, which was almost only seen in LTS tumors and proved to be an 
independent prognostic factor in multivariate analysis. In addition, we noted that WDPMs with no or 
limited invasion exhibited a similar outcome than the MPMs with polypoid growth pattern. However, 
due to small numbers in each category, further studies are required on this aspect.
The three-tier nuclear grade was another independent prognostic factor in multivariate analyses. In 
the LTS group nuclear grade I was present in over twice that of the control group, whereas grade II 
was most common observation in controls. Several studies both in pleural and peritoneum epithelioid 
mesothelioma have obtained similar results [245,331]. In addition, a multi-institutional study revealed 
that OS could be further stratified when nuclear grade was added to the presence of necrosis [246].
This was also noted in a recent multidisciplinary expert proposal for pathologic update, where it was 
suggested that all epithelioid tumors should be graded either into low-grade (nuclear grade I and II 
without necrosis) or high-grade (nuclear grade II with necrosis or nuclear grade III) based on the 
combination of nuclear grade and necrosis [108]. In contrast to nuclear grade, we found that the 
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presence of necrosis had prognostic utility only in univariate analyses. Since the proportion of 
necrosis found in these tumors was low, we could not reliably test the combination with nuclear grade. 
We also observed an association between fiber concentration found in lung tissue and nuclear grade. 
This was driven by the positive correlation with mitotic count. Mitosis is a process of cell duplication 
in which cell divides and produces identical copies of itself [332]. Thus, an increased mitotic count 
can be seen as a universal characteristic of cancerous growth, whereas the evaluation of nuclear atypia 
is a more subjective measure of nucleus size and shape.
Other histopathological features that were more common in LTS and associated with survival in 
univariate analyses but not after adjustments were morphological subtypes, the presence of single 
layer, and low tumor density in the tissue sample. Out of these features, morphological subtypes have 
been mostly studied in mesothelioma. Heterogeneity in the epithelioid subtype and its association 
with survival was shown by Kadota et al [185]. They observed that a pleomorphic subtype had the
worst survival (OS 8.1 months) followed by solid (OS 13.7 months), micropapillary (OS 15.8 
months), tubulopapillary (OS 17.9 months), and trabecular (OS 24.9 months) subtypes. They 
proposed that the first three could be combined as high-grade subtypes and trabecular and 
tubulopapillary as low-grade. We used these combinations for survival analyses due to the small 
number of tumors in some subgroups. The caveat of this method is that mesotheliomas are 
heterogenous and these subtypes are classified as a predominant growth, whereas some tumors can 
exhibit several different growth patterns. However, since they are reproducible, easy to perform, and 
have a clear survival association, we think that they should be included into routine histopathological 
evaluation. The growth of mesothelium in a single layer in tubular structures and the proportion of 
malignant mesothelial cells to other tissues within the diagnostic sample are novel features that have 
not been previously reported. We think that the first is related to the degree of differentiation in the 
tumor and analogous to well-differentiated adenocarcinomas, whereas the latter is an approximation 
of the density of the malignant cells in the diagnostic sample. They can both be affected by the size 
and site of tumor biopsy and thus challenging to import into clinical practice.
6.5 Strengths and limitations
The data collected in studies I and III-IV were based on a compilation of different registries including
patient information from hospital medical records. In addition, a thorough evaluation of CT images 
and histopathological samples was performed. We think that using multiple ways to collect data
makes the results more comprehensive. Nevertheless, the major limitation in these studies is the 
retrospective nature of a major part of the study design. This increases the potential bias in data 
collection, such as missing or incorrect information, and prevents us from drawing definite causality 
inferences [333]. However, several attempts were made in order to improve the data quality. For 
example, the radiological and histopathological features were assessed blinded to the patient 
information, several confounding factors were controlled, and the follow-up for patients was almost 
complete.
Another major limitation of these studies is the small study population size, which is due to the rarity 
of the disease. Even if we used a nationwide approach in studies III-IV, we lacked statistical power,
especially in the subgroup analyses. Thus, different stage groups, ECOG PS-groups, and epithelioid 
histopathological subtypes needed to be merged for the survival analyses. This weakens the 
generalizability of these results. In addition, the low amount of MPM patients in study II prevented 
us from studying the prognostic significance of the circulating biomarkers. 
Even if the CT scans used in our studies were performed in the same hospital district, multiple 
different protocols and techniques were used, which increases variability in the analyses. In study I,
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only a single radiologist evaluated the CT images, thus inter-reader agreement was not measured.
Having two independent radiologists would allow us to be more confident in the reproducibility of 
the CT characteristics used in these studies. However, we assessed intra-rater agreement by reviewing 
a subgroup of the images in a random order. 
Similarly, in study III and IV, one pathologist was in charge of scoring the histological samples, and 
a second opinion was asked in cases of uncertain findings. Since some of the features are subjective, 
an external validation is needed in order to properly verify these findings. In contrast to some studies 
that had used primarily larger surgical specimen [245], we mainly evaluated the first available biopsy. 
This approach can be seen as a strength as these findings are better applicable in the clinical setting,
where samples are far from standardized. However, small or bad quality specimens can complicate 
the accurate evaluation and may influence the histopathological classification of a heterogeneous 
disease such as MPM. 
We investigated how different therapies associated with survival in study IV. The role of therapy 
cannot be reliably determined in non-randomized studies, due to numerous confounding factors that
cannot be adjusted for [333]. In addition, there can also be substantial regional differences in the 
therapies offered to MPM patients and some treatment options have evolved in the 10-year study 
period. 
The fact that our LTS patients had lower TS and were lower staged at the diagnosis than the control 
group rises the possibility of lead-time bias. This usually occurs in screening studies, where a 
diagnostic approach identifies the disease earlier and creates an impression of prolonged survival 
without significant modification of the disease course [334]. This effect is difficult to measure or
adjust for in retrospective studies. However, we think that it does not significantly contribute to the 
findings of our studies, given the dismal prognosis in MPM in general and the fact that no screening 
was used. 
Finally, some selection bias may have occurred in forming the control group in studies III-IV. This 
was based on the practical approach using an already characterized cohort of patients from HUS 
region with an epithelioid histology. In contrast, the LTS group was formed from the nationwide 
cancer registry. Regional differences in the diagnosis and treatment might have affected patient 
outcome. Similarly, the assignment of presurgical patients in study II leaded to a disproportion in
different stage groups in NSCLC and MPM. However, we do not think that this significantly modified 
the results, since we did not find a clear correlation between the biomarkers and TNM stage.
61 
 
7. Conclusions
The combination of tumor thickness and pleural extension was an independent prognostic factor in 
MPM. Besides mortality, it associates with histological subgroups and TNM stage.
Circulating activins and follistatins levels were elevated in MPM compared to NSCLC and benign 
lung tumors. Out of these markers, activin A was the best one at separating these different diagnostic
groups. We found that cancer cachexia is a prevalent condition in MPM at diagnosis. In MPM 
patients, activin A levels correlated with tumor size, cancer cachexia, and poor chemotherapy 
response.
We identified 52 patients with epithelioid histology with survival of over five years. Contrary to our 
expectations, we did not find a single case where another type of malignancy would have been 
misdiagnosed as a mesothelioma. However, one patient was miscoded at the cancer registry and four
cases were found to represent other types of mesothelial tumors than diffuse MPM. Independent 
predictors for prolonged survival were ECOG performance status, tumor size, polypoid growth 
pattern, and nuclear grade.
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8. Implications and future perspectives
Results obtained in this doctoral study may aid to determine the prognosis of MPM. Whether these 
factors affect the feasibility of various treatment modalities remains to be studied.
Our studies bring forward some challenges related to CT evaluation of current T-category in the 
TNM-staging. Using quantitative measurements, such as tumor thickness, volumetry, or TS-
estimation, as proposed in our studies, could better stratify patients into different stage groups. 
The role of activins, particularly activin A, needs to be further studied in MPM. Several confounding 
factors make it unpractical for diagnostic purposes, but the association that we found in our studies 
could open a novel pathway for treatment that could lead to palliation of symptoms and possible 
therapeutic effects.
We found that asbestos exposure does not only predispose to MPM but also associates with survival. 
However, in these studies its prognostic utility vanished after adjustments, which might be because 
of the small sample size. Thus, we plan to further study this association in a large-scale study. 
More precise histological diagnosis improves risk stratification and could help in patient selection for 
certain treatments in the future. Due to the rarity and heterogeneity of the MPM tumor, some of the 
histopathological prognostic features could be difficult to implement in the clinical use. Therefore, 
we aim to test whether artificial intelligence (AI) could be used to analyze scanned tumor samples 
and if it could predict survival from the histological slides used in studies III and IV. Furthermore, 
we aim to investigate the tumor microenvironment and the genetic landscape of these tumors to
further search for prognostic associations. 
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